Amgen (AMGN) 10-K 14 Feb 25 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2024	Feb. 11, 2025	Jun. 30, 2024
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-37702
Entity Registrant Name	Amgen Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3540776
Entity Address, Address Line One	One Amgen Center Drive
Entity Address, City or Town	Thousand Oaks
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91320-1799
City Area Code	805
Local Phone Number	447-1000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 167,600,000,000
Entity Common Stock, Shares Outstanding		537,204,943
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the registrant’s Proxy Statement with respect to the 2025 Annual Meeting of Stockholders to be held on May 23, 2025, are incorporated by reference into Part III of this annual report.
Entity Central Index Key	0000318154
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Common Stock
Entity Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value
Trading Symbol	AMGN
Security Exchange Name	NASDAQ
2.00% Senior Notes Due 2026
Entity Information [Line Items]
Title of 12(b) Security	2.00% Senior Notes due 2026
Trading Symbol	AMGN26
Security Exchange Name	NASDAQ

Audit information

Audit information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Los Angeles, California
Auditor Firm ID	42

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 33,424	$ 28,190	$ 26,323
Operating expenses:
Cost of sales	12,858	8,451	6,406
Research and development	5,964	4,784	4,434
Selling, general and administrative	7,096	6,179	5,414
Other	248	879	503
Total operating expenses	26,166	20,293	16,757
Operating income	7,258	7,897	9,566
Other income (expense):
Interest expense, net	(3,155)	(2,875)	(1,406)
Other income (expense), net	506	2,833	(814)
Income before income taxes	4,609	7,855	7,346
Provision for income taxes	519	1,138	794
Net income	$ 4,090	$ 6,717	$ 6,552
Earnings per share:
Basic (in usd per share)	$ 7.62	$ 12.56	$ 12.18
Diluted (in usd per share)	$ 7.56	$ 12.49	$ 12.11
Weighted-average shares used in the calculation of earnings per share:
Basic (in shares)	537	535	538
Diluted (in shares)	541	538	541
Product sales
Revenues:
Total revenues	$ 32,026	$ 26,910	$ 24,801
Other revenues
Revenues:
Total revenues	$ 1,398	$ 1,280	$ 1,522

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 4,090	$ 6,717	$ 6,552
Other comprehensive income (loss), net of reclassification adjustments and taxes:
(Losses) gains on foreign currency translation adjustments	(76)	50	496
Gains (losses) on cash flow hedges	309	(150)	67
Other	(10)	42	2
Other comprehensive income (loss), net of reclassification adjustments and taxes	223	(58)	565
Comprehensive income	$ 4,313	$ 6,659	$ 7,117

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 11,973	$ 10,944
Trade receivables, net	6,782	7,268
Inventories	6,998	9,518
Other current assets	3,277	2,602
Total current assets	29,030	30,332
Property, plant and equipment, net	6,543	5,941
Intangible assets, net	27,699	32,641
Goodwill	18,637	18,629
Other noncurrent assets	9,930	9,611
Total assets	91,839	97,154
Current liabilities:
Accounts payable	1,908	1,590
Accrued liabilities	17,641	15,359
Current portion of long-term debt	3,550	1,443
Total current liabilities	23,099	18,392
Long-term debt	56,549	63,170
Long-term deferred tax liabilities	1,616	2,354
Long-term tax liabilities	2,349	4,680
Other noncurrent liabilities	2,349	2,326
Contingencies and commitments (see Note 20)
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—536.9 shares in 2024 and 535.4 shares in 2023	33,533	33,070
Accumulated deficit	(27,590)	(26,549)
Accumulated other comprehensive loss	(66)	(289)
Total stockholders’ equity	5,877	6,232
Total liabilities and stockholders’ equity	$ 91,839	$ 97,154

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Millions	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized (in shares)	2,750	2,750
Common stock and additional paid-in capital, shares outstanding (in shares)	536.9	535.4

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions	Total	Number of shares of common stock	Common stock and additional paid-in capital	Accumulated deficit	Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2021		558.3
Beginning balance at Dec. 31, 2021	$ 6,700		$ 32,096	$ (24,600)	$ (796)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	6,552			6,552
Other comprehensive income (loss), net of taxes	565				565
Dividends declared on common stock	(4,264)			(4,264)
Issuance of common stock in connection with equity award programs (in shares)		1.8
Issuance of common stock in connection with equity award programs	138		138
Stock-based compensation expense	419		419
Tax impact related to employee stock-based compensation expense	(139)		(139)
Repurchases of common stock (in shares)		(26.1)
Repurchases of common stock	(6,310)			(6,310)
Ending balance (in shares) at Dec. 31, 2022		534
Ending balance at Dec. 31, 2022	3,661		32,514	(28,622)	(231)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	6,717			6,717
Other comprehensive income (loss), net of taxes	(58)				(58)
Dividends declared on common stock	(4,644)			(4,644)
Issuance of common stock in connection with equity award programs (in shares)		1.4
Issuance of common stock in connection with equity award programs	95		95
Stock-based compensation expense	454		454
Equity awards issued for Horizon acquisition, net	141		141
Tax impact related to employee stock-based compensation expense	$ (134)		(134)
Ending balance (in shares) at Dec. 31, 2023	535.4	535.4
Ending balance at Dec. 31, 2023	$ 6,232		33,070	(26,549)	(289)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	4,090			4,090
Other comprehensive income (loss), net of taxes	223				223
Dividends declared on common stock	(4,931)			(4,931)
Issuance of common stock in connection with equity award programs (in shares)		2.2
Issuance of common stock in connection with equity award programs	189		189
Stock-based compensation expense	530		530
Tax impact related to employee stock-based compensation expense	(256)		(256)
Repurchases of common stock (in shares)		(0.7)
Repurchases of common stock	$ (200)			(200)
Ending balance (in shares) at Dec. 31, 2024	536.9	536.9
Ending balance at Dec. 31, 2024	$ 5,877		$ 33,533	$ (27,590)	$ (66)

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended													12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Common stock, dividends declared per share (in usd per share)	$ 2.38	$ 2.25	$ 2.25	$ 2.25	$ 2.25	$ 2.13	$ 2.13	$ 2.13	$ 2.13	$ 1.94	$ 1.94	$ 1.94	$ 1.94	$ 9.13	$ 8.64	$ 7.95

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net income	$ 4,090	$ 6,717	$ 6,552
Noncash adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	5,592	4,071	3,417
Stock-based compensation expense	530	431	401
Deferred income taxes	(1,228)	(1,273)	(1,198)
Adjustments for equity method investments	(10)	11	891
Loss on divestiture	0	0	567
Losses (gains) on equity securities	159	(1,565)	127
Other items, net	(8)	563	(303)
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	441	(1,015)	(746)
Inventories	2,532	491	(742)
Other assets	(652)	(564)	258
Accounts payable	312	(402)	154
Accrued income taxes, net	(1,011)	(1,031)	(647)
Long-term tax liabilities	(492)	371	229
Accrued liabilities	92	953	97
Accrued sales incentives and allowance	1,194	935	846
Other liabilities	(51)	(222)	(182)
Net cash provided by operating activities	11,490	8,471	9,721
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired	0	(26,989)	(3,839)
Purchases of marketable securities	0	(1)	(2,587)
Proceeds from sales of marketable securities	0	1,123	98
Proceeds from maturities of marketable securities	0	550	1,120
Purchases of property, plant and equipment	(1,096)	(1,112)	(936)
Other	50	225	100
Net cash used in investing activities	(1,046)	(26,204)	(6,044)
Cash flows from financing activities:
Net proceeds from issuance of debt	0	27,777	6,919
Extinguishment of debt	(659)	(647)	(297)
Repayment of debt	(3,600)	(1,454)	0
Repurchases of common stock	(200)	0	(6,360)
Dividends paid	(4,832)	(4,556)	(4,196)
Other	(124)	(72)	(103)
Net cash (used in) provided by financing activities	(9,415)	21,048	(4,037)
Increase (decrease) in cash and cash equivalents	1,029	3,315	(360)
Cash and cash equivalents at beginning of year	10,944	7,629	7,989
Cash and cash equivalents at end of year	$ 11,973	$ 10,944	$ 7,629

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its consolidated subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate our business in one operating segment: human therapeutics. See Note 2, Segment and other information. Principles of consolidation The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Revenues Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers. Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&A expense in the Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the R&D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur. Research and development costs R&D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs; and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 9, Collaborations. Selling, general and administrative costs SG&A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $987 million, $647 million and $841 million during the years ended December 31, 2024, 2023 and 2022, respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 9, Collaborations. Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate. Stock-based compensation We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 5, Stock-based compensation. Income taxes We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 7, Income taxes. Amgen is subject to current U.S. minimum tax on foreign subsidiaries. Based on our election beginning in 2022, we have established deferred taxes with respect to the U.S. minimum tax on the earnings of our foreign subsidiaries. This requires us to recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years. These are ongoing adjustments that are likely to occur in the future. Acquisitions We first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&D projects, and liabilities assumed are recorded in our consolidated financial statements at their respective fair values as of the acquisition date. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination, including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to our acquisition, are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 4, Acquisitions and divestitures, and Note 18, Fair value measurement. Cash equivalents We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase. Interest-bearing securities We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company’s investments that are available for current operations. See Note 10, Investments, and Note 18, Fair value measurement. Inventories Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 11, Inventories. Derivatives We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 18, Fair value measurement, and Note 19, Derivative instruments. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 12, Property, plant and equipment. Goodwill and other intangible assets Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets’ estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 13, Goodwill and other intangible assets. The fair values of IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors’ products could result in partial or full impairment of the related intangible assets. We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 13, Goodwill and other intangible assets. Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 20, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Foreign currency translation The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries’ earnings are translated into U.S. dollars by using average exchange rates. Equity investments Marketable and nonmarketable equity securities Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other income (expense), net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost less impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other income (expense), net, in the Consolidated Statements of Income. Equity method investments Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income (expense), net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value. For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income (expense), net, in the Consolidated Statements of Income. Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income (expense), net, in the Consolidated Statements of Income. Recently adopted accounting pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and additional interim segment reporting disclosures, including for companies with a single reportable segment. The standard is effective for public business entities such as Amgen for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, with retrospective application required for all prior periods presented. We adopted this standard in fiscal year 2024, which resulted in incremental segment disclosures. See Note 2, Segment and other information. Recent accounting pronouncements not yet adopted In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve income tax disclosure requirements by requiring more detailed information on several income tax disclosures, such as enhancing disclosure of income taxes paid and requiring disaggregation of the effective income tax rate reconciliation. The standard is effective for public business entities such as Amgen for annual periods beginning after December 15, 2024. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. We are currently evaluating the impact of adopting this standard on our consolidated financial statements and related disclosures. In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve disclosures about a public business entity’s expenses by requiring disaggregated disclosures of certain types of expenses, including purchases of inventory, employee compensation, depreciation, intangible amortization and depletion, as applicable, for each income statement caption that includes those expenses. In addition, the standard will require entities to define and disclose total selling expenses. The standard is effective for public business entities such as Amgen for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. We are currently evaluating the impact of adopting this standard on our consolidated financial statements and related disclosures.

Segment and other information

Segment and other information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment and other information	Segment and other information We operate our business in one operating segment, which also represents one reportable segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. The human therapeutics segment is engaged in the discovery, development, manufacturing and delivery of innovative medicines to fight some of the world’s toughest diseases. The Company’s Chief Executive Officer has been identified as the chief operating decision maker (CODM). The CODM manages and allocates resources on a consolidated basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance and allocating resources, which is reviewed on a consolidated basis. As the Company’s CODM evaluates the financial performance of the Company’s human therapeutics segment on a consolidated basis, the measure of segment performance is net income, as reflected in the Consolidated Statements of Income. The CODM uses net income to allocate resources on a consolidated basis, which enables the CODM to assess both the overall level of resources available and optimize distribution of resources across functions, therapeutic areas, regions and research and development programs in line with our long-term corporate-wide strategic goals. In addition, the CODM may also evaluate financial performance based on net income adjusted for certain items that are unusual and non-recurring. As the Company manages its assets on a consolidated basis, the measure of segment assets is total assets, as reflected in the Consolidated Balance Sheets. See Note 10, Investments, for further information regarding equity method investments, and Net cash used in investing activities in the Consolidated Statements of Cash Flows for further information regarding capital expenditures. The following table provides segment revenues, significant segment expenses, other segment items, reported segment net income and a reconciliation of segment net income to the Company’s total consolidated net income for the years ended December 31, 2024, 2023 and 2022 (in millions): Years ended December 31, 2024 2023 2022 Revenues: Product sales $ 32,026 $ 26,910 $ 24,801 Other revenues 1,398 1,280 1,522 Total revenues 33,424 28,190 26,323 Less: Manufacturing cost of sales (1)(2) 11,118 7,347 5,776 Profit share and royalties in cost of sales (1) 1,740 1,104 630 Research and development (1) 5,964 4,784 4,434 Sales and marketing (1) 4,713 3,784 3,736 General and administrative (1) 2,383 2,395 1,678 Other segment items (3) 262 (743) 777 Equity in (income) loss of equity method investments (10) 14 667 Interest income (510) (1,225) (127) Interest expense, net 3,155 2,875 1,406 Provision for income taxes 519 1,138 794 Segment net income 4,090 6,717 6,552 Reconciliation of profit or loss: Adjustments and reconciling items — — — Consolidated net income $ 4,090 $ 6,717 $ 6,552 ____________ (1) During the years ended December 31, 2024, 2023 and 2022, we recognized amortization expense on our intangible assets of $4.8 billion, $3.2 billion and $2.6 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. In addition, during the years ended December 31, 2024, 2023 and 2022, we recognized depreciation and ROU asset amortization expense of $805 million, $824 million and $818 million, respectively. (2) During the years ended December 31, 2024, 2023 and 2022, manufacturing cost of sales included amortization of step-up to fair value of inventory acquired in business combinations of $2.4 billion, $656 million and $30 million, respectively. (3) Other segment items included in Segment net income primarily consists of: (i) fair value adjustments on equity securities (see Note 10, Investments) and (ii) net impairment charges on intangible assets (see Note 13, Goodwill and other intangible assets). For the year ended December 31, 2023, other segment items also included expenses related to our restructuring plan that was both initiated and substantially completed in 2023. For the year ended December 31, 2022, other segment items also included a loss on the divestiture of Gensenta (see Note 4, Acquisitions and divestitures).

Revenues

Revenues	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenues	Revenues We operate our business in one operating segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW product sales relates to products sold in Europe. Revenues were as follows (in millions): Year ended December 31, 2024 Year ended December 31, 2023 Year ended December 31, 2022 U.S. ROW Total U.S. ROW Total U.S. ROW Total Prolia $ 2,885 $ 1,489 $ 4,374 $ 2,733 $ 1,315 $ 4,048 $ 2,465 $ 1,163 $ 3,628 ENBREL 3,288 28 3,316 3,650 47 3,697 4,044 73 4,117 XGEVA 1,507 718 2,225 1,527 585 2,112 1,480 534 2,014 Repatha 1,139 1,083 2,222 793 842 1,635 608 688 1,296 Otezla 1,699 427 2,126 1,777 411 2,188 1,886 402 2,288 TEPEZZA (1) 1,835 16 1,851 441 7 448 — — — EVENITY 1,131 432 1,563 809 351 1,160 533 254 787 KYPROLIS 948 555 1,503 921 482 1,403 850 397 1,247 Nplate 970 486 1,456 996 481 1,477 848 459 1,307 Aranesp 386 956 1,342 452 910 1,362 521 900 1,421 BLINCYTO 800 416 1,216 566 295 861 336 247 583 KRYSTEXXA (1) 1,185 — 1,185 272 — 272 — — — Vectibix 519 526 1,045 461 523 984 396 497 893 TEZSPIRE 972 — 972 567 — 567 170 — 170 Other products (2) 4,037 1,593 5,630 3,307 1,389 4,696 3,606 1,444 5,050 Total product sales (3) 23,301 8,725 32,026 19,272 7,638 26,910 17,743 7,058 24,801 Other revenues 562 836 1,398 534 746 1,280 852 670 1,522 Total revenues $ 23,863 $ 9,561 $ 33,424 $ 19,806 $ 8,384 $ 28,190 $ 18,595 $ 7,728 $ 26,323 ____________ (1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date. (2) Consists of product sales of our non-principal products. (3) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2024, 2023 and 2022. In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance. For each of the years ended December 31, 2024, 2023 and 2022, we had product sales to three customers that individually accounted for more than 10% of total revenues. For the year ended December 31, 2024, on a combined basis, these customers accounted for 77% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions): Years ended December 31, 2024 2023 2022 McKesson Corporation: Gross product sales $ 22,173 $ 19,035 $ 17,305 % of total gross revenues 33 % 33 % 35 % Cencora, Inc.: Gross product sales $ 18,387 $ 16,625 $ 15,443 % of total gross revenues 27 % 29 % 31 % Cardinal Health, Inc.: Gross product sales $ 11,278 $ 9,775 $ 8,319 % of total gross revenues 17 % 17 % 16 % As of December 31, 2024 and 2023, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 70% and 75%, respectively, of net trade receivables on a combined basis. As of December 31, 2024 and 2023, 26% and 22%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2024 and 2023, was not material.

Acquisitions and divestitures

Acquisitions and divestitures	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions and divestitures	Acquisitions and divestitures Acquisition of Horizon Therapeutics plc On October 6, 2023, Amgen completed its acquisition of Horizon by acquiring all of the outstanding shares of Horizon for $116.50 per share in cash, representing a total consideration of approximately $27.8 billion. Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs of patients impacted by rare, autoimmune and severe inflammatory diseases. The acquisition, which was accounted for as a business combination, aligns with Amgen’s core strategy of delivering innovative medicines that make a significant difference for patients suffering from serious diseases and strengthens Amgen’s leading rare disease portfolio by adding first-in-class, early-in-lifecycle medicines, including TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic refractory gout and UPLIZNA for neuromyelitis optica spectrum disorder. Upon its acquisition, Horizon became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date. During the year ended December 31, 2024, the purchase price allocation of the acquisition was completed and measurement period adjustments were finalized, which included changes to the purchase price allocation that resulted in a net increase of approximately $25 million to goodwill. The measurement period adjustments resulted primarily from adjustments to acquired assets and liabilities, including deferred tax attributes, based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. The adjustments did not have a significant impact on Amgen’s results of operations during the year ended December 31, 2024, and would not have had a significant impact on prior-period results if the adjustments had been made as of the acquisition date. The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement-period adjustments (in millions): Cash and cash equivalents $ 681 Inventories 5,014 Property, plant and equipment, net 318 Finite-lived intangible assets—developed-product-technology rights 19,590 IPR&D 1,060 Goodwill 3,136 Deferred tax asset 795 Deferred tax liability (2,488) Other assets and liabilities, net (273) Total assets acquired, net of liabilities assumed $ 27,833 The $27.8 billion total consideration for this transaction consisted of (i) cash consideration transferred to common shareholders of $26.7 billion; (ii) cash consideration transferred to vested and outstanding options, outstanding RSU awards and outstanding performance share unit awards of $523 million; (iii) fair value of Amgen replacement awards (based on conversion of outstanding employee RSU awards) of $180 million representing noncash consideration; and (iv) a portion of Horizon’s debt, settled by Amgen on the acquisition closing date, of $382 million. Amgen issued 1.7 million replacement equity awards with the original vesting conditions, the fair value of which was determined based on the acquisition date fair value based on the conversion calculation. See Note 5, Stock-based compensation. The estimated fair values of $20.7 billion for the developed-product-technology rights and IPR&D intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately 10 years from the acquisition date using the straight-line methodology. The estimated fair value of the acquired inventory of $5.0 billion was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer’s effort are applied. The inventory fair value adjustment is being amortized using a weighted-average inventory turnover, which we estimate to approximate 27 months from the acquisition date. A deferred tax liability of $2.5 billion was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired, as well as associated deferred tax asset for anticipatory foreign tax credits of $795 million. The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $3.1 billion was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from the marketed products acquired and other benefits. During the three months ended December 31, 2023, the Company incurred approximately $487 million of acquisition costs related to the closing of our Horizon acquisition, consisting of $167 million for share-based payments to settle non-vested equity awards attributable to post-combination services, severance and other employee-related expenses and $320 million for transaction costs. These costs were included primarily in SG&A expense in the Consolidated Statements of Income. Supplemental Pro Forma Financial Information The following table presents the unaudited supplemental pro forma results of a hypothetical combined Amgen and Horizon entity for the years ended December 31, 2023 and 2022, as if the acquisition of Horizon had occurred on January 1, 2022 (in millions): Years ended December 31, 2023 2022 Total revenues $ 30,969 $ 29,964 Net income $ 5,383 $ 2,381 The unaudited supplemental pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Amgen and Horizon. In order to reflect the occurrence of the acquisition on January 1, 2022, the unaudited supplemental pro forma financial information includes adjustments to reflect: (i) incremental amortization expense based on the fair values of the identifiable intangible assets and inventory step-up; (ii) the additional interest expense associated with the issuance of debt to finance the acquisition; (iii) the reclassification of transaction and other acquisition-related costs incurred during the three months ended December 31, 2023, to the year ended December 31, 2022; and (iv) the income tax impact using an estimated effective tax rate applied to the combined entity. The unaudited supplemental pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2022. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company, nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. Acquisition of ChemoCentryx, Inc. On October 20, 2022, we acquired all of the outstanding stock of ChemoCentryx, a publicly traded biotechnology company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52.00 per share in cash, representing a total consideration of $3.9 billion. The acquisition, which was accounted for as a business combination, includes TAVNEOS, an orally administered selective complement 5a receptor inhibitor that was approved by the FDA in October 2021 as an adjunctive therapy for adults with severe active antineutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). TAVNEOS is commercialized by us in the United States; for markets outside the United States, TAVNEOS is commercialized by a collaboration partner, and Amgen is entitled to royalties and milestones based on future sales of the product. Upon its acquisition, ChemoCentryx became a wholly owned subsidiary of Amgen, and its operations became included in our consolidated financial statements commencing on the acquisition date. Measurement-period adjustments during the year ended December 31, 2023, included changes in the purchase price allocation and total consideration, resulting in a net decrease of approximately $18 million to goodwill. The adjustments did not have a significant impact on Amgen’s results of operations during the year ended December 31, 2023, and would not have had a significant impact on prior-period results if the adjustments had been made as of the acquisition date. The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement-period adjustments (in millions): Cash and cash equivalents $ 86 Marketable securities 235 Inventories 41 Finite-lived intangible assets—developed-product-technology rights 3,499 Goodwill 649 Other liabilities, net (83) Deferred tax liability, net (502) Total assets acquired, net of liabilities assumed $ 3,925 The $3.9 billion total consideration consisted of (i) a $3.7 billion cash payment to outstanding common stockholders of ChemoCentryx and (ii) a $181 million cash payment to equity award holders of ChemoCentryx for services rendered prior to the acquisition date of October 20, 2022, under the ChemoCentryx equity award plans. The developed-product-technology rights acquired relates to TAVNEOS, which is approved in the United States and the EU for ANCA-associated vasculitis. The estimated fair value of $3.5 billion was determined by using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately 11 years from the acquisition date using the straight-line methodology. The estimated fair value of the acquired inventory of $41 million was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer’s effort are applied. The inventory fair value adjustment was amortized as inventory turned over, which we estimated to be approximately 13 months from the acquisition date. A net deferred tax liability of $502 million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired. The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $649 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value is primarily attributable to the expected synergies from the TAVNEOS asset. Divestiture of Gensenta İlaç Sanayi ve Ticaret A.Ş. On November 2, 2022, we sold our shares in Gensenta, a subsidiary in Turkey, to Eczacıbaşı for net cash proceeds of approximately $130 million. The transaction was accounted for as a sale of a business and did not meet the criteria to be classified as discontinued operations. Upon closing of this transaction, net assets related to Gensenta of $86 million were divested, and during the year ended December 31, 2022, we recognized a loss on divestiture of $567 million recorded in Other operating expenses in the Consolidated Statements of Income, primarily due to the reclassification of $615 million of cumulative foreign currency translation losses from AOCI into earnings. See Note 17, Stockholders’ equity.

Stock-based compensation

Stock-based compensation	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2024, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 59 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose. The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions): Years ended December 31, 2024 2023 2022 RSUs $ 351 $ 309 $ 227 Performance units 133 121 132 Stock options 46 43 42 Total stock-based compensation expense, pretax 530 473 401 Tax benefit from stock-based compensation expense (114) (102) (86) Total stock-based compensation expense, net of tax $ 416 $ 371 $ 315 Restricted stock units and stock options Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee’s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs. Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient. Restricted stock units The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period, except with respect to certain holders of Horizon unvested RSUs who were granted replacement Amgen RSUs in 2023 under the original terms of the awards in connection with the Horizon acquisition based on the terms of the transaction. See Note 4, Acquisitions and divestitures. Subsequent to the Horizon acquisition, $42 million of the RSUs were accelerated and cash settled in 2023. The weighted-average grant date fair values per unit of RSUs granted (excluding replacement awards granted to Horizon RSU holders) during the years ended December 31, 2024, 2023 and 2022, were $301.36, $237.70 and $234.47, respectively. The following table summarizes information regarding our RSUs: Year ended December 31, 2024 Units Weighted-average Balance nonvested as of December 31, 2023 3.9 $ 246.43 Granted 1.5 $ 301.36 Vested (1.6) $ 250.80 Forfeited (0.3) $ 267.28 Balance nonvested as of December 31, 2024 3.5 $ 265.07 The total grant date fair values of RSUs that vested during the years ended December 31, 2024, 2023 and 2022, were $401 million, $309 million and $192 million, respectively. Stock options The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black–Scholes option valuation model to estimate the grant date fair value of stock options. The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows: Years ended December 31, 2024 2023 2022 Closing price of our common stock on grant date $ 300.30 $ 235.97 $ 230.92 Expected volatility (average of implied and historical volatility) 26.9 % 23.3 % 24.5 % Expected life (in years) 5.7 5.7 5.7 Risk-free interest rate 4.4 % 3.4 % 2.8 % Expected dividend yield 3.2 % 3.5 % 3.3 % Fair value of stock options granted $ 69.34 $ 41.86 $ 42.43 The following table summarizes information regarding our stock options: Year ended December 31, 2024 Options Weighted- Weighted- Aggregate Balance unexercised as of December 31, 2023 5.9 $ 213.90 Granted 0.8 $ 300.32 Exercised (0.6) $ 201.22 Expired/forfeited (0.2) $ 248.94 Balance unexercised as of December 31, 2024 5.9 $ 225.84 6.3 $ 236 Vested or expected to vest as of December 31, 2024 5.7 $ 224.34 6.2 $ 234 Exercisable as of December 31, 2024 3.1 $ 202.02 4.6 $ 182 The total intrinsic values of options exercised during the years ended December 31, 2024, 2023 and 2022, were $70 million, $33 million and $67 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2024, 2023 and 2022, were $15 million, $7 million and $14 million, respectively. As of December 31, 2024, $510 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years. Performance units Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2024, 2023 and 2022, which are accounted for as equity awards, are based on (i) Amgen’s total stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen’s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned. We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows: Years ended December 31, 2024 2023 2022 Closing price of our common stock on grant date $ 300.30 $ 235.97 $ 230.92 Volatility 22.1 % 21.6 % 28.1 % Risk-free interest rate 4.6 % 3.7 % 0.3 % Fair value of units granted $ 321.61 $ 252.49 $ 247.48 The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units. As of December 31, 2024 and 2023, 1.4 million and 1.7 million performance units were outstanding, respectively, with weighted-average grant date fair values per unit of $263.86 and $251.41 per unit, respectively. During the year ended December 31, 2024, 0.3 million performance units with a weighted-average grant date fair value per unit of $321.61 were granted, and 0.1 million performance units with a weighted-average grant date fair value per unit of $261.03 were forfeited. The total fair values of performance units paid during the years ended December 31, 2024, 2023 and 2022, were $182 million, $109 million and $150 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period. As of December 31, 2024, $87 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year.

Defined contribution plan

Defined contribution plan	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Defined contribution plan	Defined contribution plan The Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $375 million, $311 million and $243 million for the years ended December 31, 2024, 2023 and 2022, respectively.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Income before income taxes included the following (in millions): Years ended December 31, 2024 2023 2022 Domestic $ 4,040 $ 4,047 $ 3,026 Foreign 569 3,808 4,320 Total income before income taxes $ 4,609 $ 7,855 $ 7,346 The provision for income taxes included the following (in millions): Years ended December 31, 2024 2023 2022 Current provision: Federal $ 965 $ 1,524 $ 1,721 State 33 43 44 Foreign 759 786 304 Total current provision 1,757 2,353 2,069 Deferred benefit: Federal (860) (1,124) (1,185) State (18) (25) (27) Foreign (360) (66) (63) Total deferred benefit (1,238) (1,215) (1,275) Total provision for income taxes $ 519 $ 1,138 $ 794 Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. As of December 31, 2022, we elected to establish deferred taxes with respect to the U.S. minimum tax on the earnings of our foreign subsidiaries for the reversal of temporary items in future years. Significant components of our deferred tax assets and liabilities were as follows (in millions): December 31, 2024 2023 Deferred income tax assets: NOL and credit carryforwards $ 1,352 $ 1,465 Accrued expenses 693 668 Capitalized research and development expenses 1,762 1,333 Investments 1 — Expenses capitalized for tax 200 210 Earnings of foreign subsidiaries 1,496 1,260 Stock-based compensation 130 159 Other 361 416 Total deferred income tax assets 5,995 5,511 Valuation allowance (1,019) (957) Net deferred income tax assets 4,976 4,554 Deferred income tax liabilities: Acquired intangible assets (2,573) (3,028) Debt (264) (268) Fixed assets (143) (140) Fair value of acquired inventory (114) (349) Investments — (99) Other (244) (224) Total deferred income tax liabilities (3,338) (4,108) Total deferred income taxes, net $ 1,638 $ 446 The Company has determined that unremitted foreign earnings are not considered indefinitely reinvested to the extent foreign earnings can be distributed without a significant tax cost. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities of the tax laws and assumptions we would have to make. Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. The valuation allowance increased in 2024, primarily driven by the Company’s expectation that certain state R&D credits will expire unused. As of December 31, 2024, we had $195 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided a $17 million valuation allowance on those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2025 and 2045. We had $1.2 billion of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $1.1 billion of those state tax credit carryforwards. We had $83 million of tax credit carryforwards related to our foreign jurisdictions available to offset future foreign income taxes for which we have provided a $53 million valuation allowance. As of December 31, 2024, we had $239 million of federal NOL carryforwards available to reduce future federal income taxes and have provided no valuation allowance on those federal NOL carryforwards. Additionally, $201 million of those federal NOL carryforwards have no expiration; the remainder begin to expire between 2025 and 2033. We had $957 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $822 million of those state NOL carryforwards. We had $1.1 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $164 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $160 million have no expiration; and the remainder will expire between 2025 and 2034. The reconciliations of the total gross amounts of UTBs were as follows (in millions): Years ended December 31, 2024 2023 2022 Beginning balance $ 4,012 $ 3,770 $ 3,546 Additions based on tax positions related to the current year 188 196 151 Additions based on tax positions related to prior years 9 56 90 Reductions for tax positions of prior years (12) — (14) Reductions for expiration of statute of limitations (9) (4) (3) Settlements (4) (6) — Ending balance $ 4,184 $ 4,012 $ 3,770 Substantially all of the UTBs as of December 31, 2024, if recognized, would affect our effective tax rate . As a result, we remeasured our UTBs accordingly. Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2024, 2023 and 2022, we recognized $282 million, $287 million and $189 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2024, was primarily due to an IRS advance deposit of $800 million paid during the first quarter of 2024. As of December 31, 2024 and 2023, accrued interest and penalties associated with UTBs were $1.6 billion and $1.4 billion, respectively. The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows: Years ended December 31, 2024 2023 2022 Federal statutory tax rate 21.0 % 21.0 % 21.0 % Foreign earnings (5.8) % (5.1) % (5.6) % Foreign-derived intangible income (3.0) % (1.3) % (1.3) % Credits, Puerto Rico excise tax — % 0.3 % (2.8) % Interest on uncertain tax positions 4.2 % 2.6 % 1.9 % Credits, primarily federal R&D (5.4) % (3.5) % (2.0) % Other, net 0.3 % 0.5 % (0.4) % Effective tax rate 11.3 % 14.5 % 10.8 % The effective tax rates for the years ended December 31, 2024, 2023 and 2022, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from locations where the Company has significant manufacturing operations, including Singapore, Ireland and Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2050. Additionally, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2036. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5% and to the OECD’s 15% global minimum tax in jurisdictions where enacted. Beginning on January 1, 2023, we were no longer subject to a 4% excise tax in the U.S. territory of Puerto Rico on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We qualify for and are subject to the alternative income tax rate on industrial development income of our Puerto Rico affiliate. In the United States, this income tax qualifies for foreign tax credits. Both this income tax and the associated foreign tax credits are generally recognized in our provision for income taxes. We accounted for the 2022 excise tax that was capitalized in Inventories as an expense in Cost of sales when the related products were sold in the first half of 2023, and a foreign tax credit was not recognized with respect to the excise tax expense in 2023. We did not have this excise tax exposure in 2024. Income taxes paid during the years ended December 31, 2024, 2023 and 2022, were $2.9 billion, $3.4 billion and $2.4 billion, respectively. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can arise and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters. In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010–2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010–2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for the years 2010–2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. In 2020, we received an RAR and a modified RAR from the IRS for the years 2013–2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013–2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013–2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We are contesting the 2010–2012 and 2013–2015 Notices through the judicial process. The two cases were consolidated in the U.S. Tax Court on December 19, 2022. The trial began on November 4, 2024 and concluded on January 17, 2025. With the conclusion of the trial, the parties will file post-trial briefs and make closing arguments in 2025. The Company expects a decision from the Tax Court no earlier than 2026. We are currently under examination by the IRS for the years 2016–2018 with respect to issues similar to those for the 2010 through 2015 period. We believe that the IRS may also seek to continue to audit similar issues related to the allocation of income between the United States and the U.S. territory of Puerto Rico for years beyond 2018. In addition, we are under examination by a number of state and foreign tax jurisdictions. Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.

Earnings per share

Earnings per share	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings per share	Earnings per share The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method. The computations for basic and diluted EPS were as follows (in millions, except per-share data): Years ended December 31, 2024 2023 2022 Income (Numerator): Net income for basic and diluted EPS $ 4,090 $ 6,717 $ 6,552 Shares (Denominator): Weighted-average shares for basic EPS 537 535 538 Effect of dilutive securities 4 3 3 Weighted-average shares for diluted EPS 541 538 541 Basic EPS $ 7.62 $ 12.56 $ 12.18 Diluted EPS $ 7.56 $ 12.49 $ 12.11 For each of the three years ended December 31, 2024, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	Collaborations A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity. From time to time, we enter into collaborative arrangements for the R&D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalties and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below. AstraZeneca plc We are in a collaboration with AstraZeneca for the development and commercialization of TEZSPIRE. Under our collaboration, both companies share global costs, profits and losses equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. AstraZeneca leads global development. In North America, Amgen, as the principal, recognizes product sales of TEZSPIRE in the United States, and AstraZeneca, as the principal, recognizes product sales of TEZSPIRE in Canada. AstraZeneca leads commercialization for TEZSPIRE outside North America. Amgen manufactures and supplies TEZSPIRE worldwide. During the years ended December 31, 2024, 2023 and 2022, global profit and loss share expenses were $412 million, $310 million and $119 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. Net costs due to AstraZeneca for global development and commercialization were not material during the years ended December 31, 2024, 2023 and 2022. TEZSPIRE launched in the United States in January 2022. UCB We are in a collaboration with UCB for the development and commercialization of EVENITY. Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe. Amgen, as the principal, leads commercialization for EVENITY and recognizes product sales in all other territories, including the United States. Global development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide. During the years ended December 31, 2024, 2023 and 2022, global profit and loss share expenses were $547 million, $396 million and $255 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2024, 2023 and 2022, were not material. BeiGene, Ltd. In January 2020, we acquired an equity stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 10, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen would pay royalties to BeiGene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene. In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits and losses equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen also pays royalties to BeiGene. During the years ended December 31, 2024, 2023 and 2022, net costs recovered from BeiGene for oncology product candidates were $122 million, $109 million and $199 million, respectively, and were recorded as an offset to R&D expense in the Consolidated Statements of Income. During the years ended December 31, 2024, 2023 and 2022, product sales from Amgen to BeiGene under the collaboration were $259 million, $125 million and $64 million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. Profit and loss share expenses related to the initial product-specific commercialization period were not material during the years ended December 31, 2024, 2023 and 2022. Kyowa Kirin Co., Ltd. We are in a collaboration and licensing agreement with Kyowa Kirin to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases. Under the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. Kyowa Kirin will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia. We made an upfront payment of $400 million to Kyowa Kirin that was recognized in R&D expense in the third quarter of 2021. Amgen and Kyowa Kirin share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by Kyowa Kirin will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850 million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay Kyowa Kirin significant double-digit royalties on global sales, except in Japan. During the years ended December 31, 2024, 2023 and 2022, net costs recovered from Kyowa Kirin were $166 million, $93 million and $23 million, respectively, and were recorded as an offset to R&D expense in the Consolidated Statements of Income. Other In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts, or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties, or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.

Investments

Investments	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are classified as available for sale, by type of security were as follows (in millions): Types of securities as of December 31, 2024 Amortized Gross Gross Fair U.S. Treasury bills $ 997 $ — $ — $ 997 Money market mutual funds 10,354 — — 10,354 Other short-term interest-bearing securities 135 — — 135 Total available-for-sale investments $ 11,486 $ — $ — $ 11,486 Types of securities as of December 31, 2023 Amortized Gross Gross Fair U.S. Treasury bills $ — $ — $ — $ — Money market mutual funds 10,266 — — 10,266 Other short-term interest-bearing securities 138 — — 138 Total available-for-sale investments $ 10,404 $ — $ — $ 10,404 The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions): December 31, Consolidated Balance Sheets locations 2024 2023 Cash and cash equivalents $ 11,486 $ 10,404 Total available-for-sale investments $ 11,486 $ 10,404 Cash and cash equivalents in the above table excludes bank account cash of $487 million and $540 million as of December 31, 2024 and 2023, respectively. All interest-bearing securities as of December 31, 2024 and 2023, mature in one year or less. For the years ended December 31, 2024, 2023 and 2022, interest income on these investments was $510 million, $1.2 billion and $127 million, respectively. For the years ended December 31, 2024, 2023 and 2022, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other income (expense), net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. Equity securities BeiGene, Ltd. On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8 billion, substantially all of which was attributed to the fair value of equity securities, and we began using the equity method of accounting for this investment. Since the fair value of equity securities acquired exceeded our proportionate share of the carrying value of BeiGene’s underlying net assets, we began amortizing the intangible assets that gave rise to this basis difference over their useful lives. Effective January 30, 2023, we relinquished our right to appoint a director to BeiGene’s Board of Directors. We no longer have the ability to exert significant influence over BeiGene. As a result, in the first quarter of 2023, we began to account for our ownership interest as an equity security with a readily determinable fair value, which is carried at fair value with changes in fair value recorded in Other income (expense), net, in the Consolidated Statements of Income. See Note 18, Fair value measurement. During the years ended December 31, 2024 and 2023, we recognized unrealized gains of $82 million and $1.2 billion, respectively, in Other income (expense), net, in the Consolidated Statements of Income. As of December 31, 2024 and 2023, the fair values of our investment in BeiGene were $3.5 billion and $3.4 billion, respectively, and were included in Other noncurrent assets in the Consolidated Balance Sheets. During the year ended December 31, 2022, under the equity method of accounting, the carrying value of the investment was reduced by our share of BeiGene’s net losses of $394 million and amortization of the basis difference of $190 million, with such amounts recognized in Other income (expense), net. In addition, during the year ended December 31, 2022, the carrying value increased by $11 million from the impact of other BeiGene ownership transactions. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 9, Collaborations. Subject to certain exceptions or otherwise agreed to by BeiGene, while Amgen holds at least 5.0% of BeiGene’s outstanding common stock, (A) we may only sell our BeiGene equity investment via: (i) a registered public offering, (ii) a sale under Rule 144 of the Securities Act of 1933 (the “Securities Act”) or (iii) a private sale exempt from registration requirements under the Securities Act, and (B) we may not sell more than 5.0% of BeiGene’s outstanding common stock in any rolling 12-month period. Other equity securities Excluding our equity investments in BeiGene (discussed above) and Neumora (discussed below), we held investments in other equity securities with readily determinable fair values (publicly traded securities) of $314 million and $494 million as of December 31, 2024 and 2023, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2024, 2023 and 2022, net unrealized gains and losses on publicly traded securities resulted in a net loss of $21 million , a net gain of $98 million and a net loss of $165 million , respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2024, 2023 and 2022, were not material. We held investments of $319 million and $309 million in equity securities without readily determinable fair values as of December 31, 2024 and 2023, respectively, which are included in Other noncurrent ass ets in the Consolidated Balance Sheets. For the years ended December 31, 2024, 2023 and 2022 , gains due to upward adjustments and gains realized upon dispositions of these securities were not material. For the years ended December 31, 2024 and 2023 , downward adjustments were not material. For the year ended December 31, 2022, down ward adjustments to the carrying values of these securities were $67 million. Adjustments were based on observable price transactions. Equity Method Investments Neumora Therapeutics, Inc. As of December 31, 2024 and 2023, our ownership interests in Neumora were approximately 21.9% and 23.2%, respectively, and the fair values of our investment were $375 million and $603 million, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. Although our equity investment qualifies us for the equity method of accounting, we have elected the fair value option to account for our investment. See Note 18, Fair value measurement. Under the fair value option, changes in the fair value of the investment are recognized through earnings in Other income (expense), net, in the Consolidated Statements of Income each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. During the years ended December 31, 2024, 2023 and 2022 , we recognized unrealized losses of $228 million and unrealized gains of $238 million and $105 million, respectively, for the change in fair values in Other income (expense), net, in the Consolidated Statements of Income. On January 2, 2025, Neumora released results of a Phase 3 study of navacaprant, and Neumora’s stock price declined. We are contractually restricted from selling more than 5.0% of Neumora’s outstanding common stock in any rolling 12-month period for as long as we hold at least 10.0% of their outstanding common stock, subject to certain exceptions or otherwise agreed to by Neumora. Limited partnerships We held limited partnership investments $133 million . For the years ended December 31, 2024 and 2023, net gains and losses recognized from our limited partnership investments were not material. For the year ended December 31, 2022, net losses recognized from our limited partnership investments were $284 million .

Inventories

Inventories	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in millions): December 31, 2024 2023 Raw materials $ 818 $ 993 Work in process 4,120 5,747 Finished goods 2,060 2,778 Total inventories (1) $ 6,998 $ 9,518 ____________ (1) The decrease to Inventories during the year ended December 31, 2024, was primarily due to amortization of the inventory step-up to fair value related to acquired inventory from the Horizon acquisition. See Note 4, Acquisitions and divestitures.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment Property, plant and equipment consisted of the following (dollar amounts in millions): December 31, Useful life (in years) 2024 2023 Land — $ 346 $ 339 Buildings and improvements 10-40 4,803 4,507 Manufacturing equipment 8-12 3,291 3,220 Laboratory equipment 8-12 1,345 1,346 Fixed equipment 12 2,592 2,526 Capitalized software 3-5 1,442 1,320 Other 5-10 1,059 941 Construction in progress — 2,053 1,550 Property, plant and equipment, gross 16,931 15,749 Less accumulated depreciation and amortization (10,388) (9,808) Property, plant and equipment, net $ 6,543 $ 5,941 During the years ended December 31, 2024, 2023 and 2022, we recognized depreciation and amortization expense associated with our property, plant and equipment of $694 million, $685 million and $661 million, respectively. Geographic information Certain geographic information with respect to property, plant and equipment, net, was as follows (in millions): December 31, 2024 2023 U.S. $ 4,156 $ 3,658 Puerto Rico 1,174 1,148 ROW 1,213 1,135 Total property, plant and equipment, net $ 6,543 $ 5,941

Goodwill and other intangible a

Goodwill and other intangible assets	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Goodwill The changes in the carrying amounts of goodwill were as follows (in millions): December 31, 2024 2023 Beginning balance $ 18,629 $ 15,529 Changes to goodwill resulting from acquisitions, net (1) 25 3,089 Foreign currency translation adjustments (17) 11 Ending balance $ 18,637 $ 18,629 ____________ (1) For 2024, changes to Goodwill consisted of measurement-period adjustments related to our Horizon acquisition. For 2023, changes to Goodwill primarily consisted of goodwill resulting from our Horizon acquisition. See Note 4, Acquisitions and divestitures. Other intangible assets Other intangible assets consisted of the following (in millions): December 31, 2024 2023 Gross Accumulated Other intangible Gross Accumulated Other intangible Finite-lived intangible assets: Developed-product-technology rights $ 48,611 $ (22,594) $ 26,017 $ 48,631 $ (18,049) $ 30,582 Licensing rights 3,875 (3,392) 483 3,865 (3,265) 600 Marketing-related rights 1,202 (1,202) — 1,339 (1,264) 75 R&D technology rights 1,374 (1,235) 139 1,394 (1,228) 166 Total finite-lived intangible assets 55,062 (28,423) 26,639 55,229 (23,806) 31,423 Indefinite-lived intangible assets: In-process research and development 1,060 — 1,060 1,218 — 1,218 Total other intangible assets $ 56,122 $ (28,423) $ 27,699 $ 56,447 $ (23,806) $ 32,641 Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertain to technologies used in R&D that have alternative future uses. IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&D projects may vary from their estimated fair values. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the year ended December 31, 2023, the development of AMG 340 acquired in connection with our Teneobio acquisition was terminated, resulting in an impairment charge of $783 million, which was recognized in Other operating expenses The Company monitors intangible assets for impairment on a quarterly basis. The Developed-product-technology rights intangible asset related to Otezla has a carrying value of $5.2 billion as of December 31, 2024. In January 2025, Otezla was selected by CMS for Medicare price setting under the IRA that will be applicable beginning on January 1, 2027. Future changes to the Company’s estimates of the impact of the price negotiations under the IRA, as well as regulatory, market and competitive developments, could unfavorably impact the Company’s ability to recover the carrying value of the related intangible asset. During the years ended December 31, 2024, 2023 and 2022, we recognized amortization associated with our finite-lived intangible assets of $4.8 billion, $3.2 billion and $2.6 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2025, 2026, 2027, 2028 and 2029, is $4.5 billion, $3.9 billion, $3.9 billion, $2.9 billion and $2.2 billion, respectively.

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases We lease certain facilities and equipment related primarily to R&D, administrative and commercial activities. Leases with terms of 12 months or less are expensed as incurred and are not recorded in the Consolidated Balance Sheets. Most leases include one or more options to renew, with renewal terms that may extend the lease term up to ten years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&D and administrative spaces. The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions): December 31, Consolidated Balance Sheets locations 2024 2023 Assets: Other noncurrent assets $ 557 $ 651 Liabilities: Accrued liabilities $ 107 $ 119 Other noncurrent liabilities 673 691 Total lease liabilities $ 780 $ 810 The components of net lease costs were as follows (in millions): Years ended December 31, Lease costs 2024 2023 2022 Operating (1) $ 219 $ 208 $ 218 Sublease income (17) (28) (32) Total net lease costs $ 202 $ 180 $ 186 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2024, 2023 and 2022. Maturities of lease liabilities as of December 31, 2024, were as follows (in millions): Maturity dates Amounts 2025 $ 110 2026 129 2027 112 2028 91 2029 73 Thereafter 426 Total lease payments (1) 941 Less imputed interest (161) Present value of lease liabilities $ 780 ____________ (1) Includes future rental commitments for abandoned leases of $51 million. We expect to receive total future rental income of $54 million related to noncancellable subleases for abandoned facilities. The weighted-average remaining lease terms and weighted-average discount rates were as follows: December 31, 2024 2023 Weighted-average remaining lease term (in years) 9.3 9.7 Weighted-average discount rate 3.7 % 3.6 % Cash and noncash information related to our leases was as follows (in millions): Years ended December 31, 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 156 $ 182 $ 171 ROU assets obtained in exchange for lease obligations: Operating leases $ 126 $ 245 $ 191 As of December 31, 2024, there were no future lease payments for leases that have not yet commenced.

Other current assets and accrue

Other current assets and accrued liabilities	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Other current assets and accrued liabilities	Other current assets and accrued liabilities Other current assets consisted of the following (in millions): December 31, 2024 2023 Prepaid expenses $ 2,139 $ 1,647 Corporate partner receivables 521 502 Tax receivables 198 172 Other 419 281 Total other current assets $ 3,277 $ 2,602 Accrued liabilities consisted of the following (in millions): December 31, 2024 2023 Sales deductions $ 8,405 $ 7,271 Income taxes payable 2,583 1,664 Employee compensation and benefits 1,329 1,381 Dividends payable 1,278 1,205 Accrued interest payable 867 936 Other 3,179 2,902 Total accrued liabilities $ 17,641 $ 15,359

Financing arrangements

Financing arrangements	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Financing arrangements	Financing arrangements Our borrowings consisted of the following (in millions): December 31, 2024 2023 3.625% notes due 2024 (3.625% 2024 Notes) $ — $ 1,400 1.90% notes due 2025 (1.90% 2025 Notes) 500 500 5.25% notes due 2025 (5.25% 2025 Notes) 2,000 2,000 Term loan due April 2025 — 2,000 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 777 828 5.507% notes due 2026 (5.507% 2026 Notes) 1,500 1,500 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 Term loan due October 2026 1,800 2,000 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 595 605 2.20% notes due 2027 (2.20% 2027 Notes) 1,724 1,724 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 5.15% notes due 2028 (5.15% 2028 Notes) 3,750 3,750 1.65% notes due in 2028 (1.65% 2028 Notes) 1,234 1,234 3.00% notes due 2029 (3.00% 2029 Notes) 750 750 4.05% notes due 2029 (4.05% 2029 Notes) 1,250 1,250 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 876 892 2.45% notes due 2030 (2.45% 2030 Notes) 1,250 1,250 5.25% notes due 2030 (5.25% 2030 Notes) 2,750 2,750 2.30% notes due 2031 (2.30% 2031 Notes) 1,250 1,250 2.00% notes due 2032 (2.00% 2032 Notes) 1,001 1,001 3.35% notes due 2032 (3.35% 2032 Notes) 1,000 1,000 4.20% notes due 2033 (4.20% 2033 Notes) 750 750 5.25% notes due 2033 (5.25% 2033 Notes) 4,250 4,250 6.375% notes due 2037 (6.375% 2037 Notes) 478 478 6.90% notes due 2038 (6.90% 2038 Notes) 254 254 6.40% notes due 2039 (6.40% 2039 Notes) 333 333 3.15% notes due 2040 (3.15% 2040 Notes) 1,668 1,803 5.75% notes due 2040 (5.75% 2040 Notes) 373 373 2.80% notes due 2041 (2.80% 2041 Notes) 776 949 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 729 729 5.65% notes due 2042 (5.65% 2042 Notes) 415 415 5.60% notes due 2043 (5.60% 2043 Notes) 2,750 2,750 5.375% notes due 2043 (5.375% 2043 Notes) 185 185 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 3.375% notes due 2050 (3.375% 2050 Notes) 1,764 2,132 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 3.00% notes due 2052 (3.00% 2052 Notes) 890 999 4.20% notes due 2052 (4.20% 2052 Notes) 895 950 4.875% notes due 2053 (4.875% 2053 Notes) 1,000 1,000 5.65% notes due 2053 (5.65% 2053 Notes) 4,250 4,250 2.77% notes due 2053 (2.77% 2053 Notes) 940 940 December 31, 2024 2023 4.40% notes due 2062 (4.40% 2062 Notes) 1,165 1,200 5.75% notes due 2063 (5.75% 2063 Notes) 2,750 2,750 Other notes due 2097 100 100 Total principal amount of debt 61,778 66,330 Unamortized bond discounts, premiums and issuance costs, net (1,360) (1,420) Fair value adjustments (343) (314) Other 24 17 Total carrying value of debt 60,099 64,613 Less current portion (3,550) (1,443) Total long-term debt $ 56,549 $ 63,170 There are no material differences between the effective interest rates and coupon rates of our notes, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively. Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes—except our Other notes due 2097—may be redeemed at any time at our option—in whole or in part—at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity, except for the 5.507% 2026 Notes, which may be redeemed without payment of the make-whole amount if redemption occurs after two years prior to maturity. Debt issuances and acquisition-related financing We did not issue debt securities during the year ended December 31, 2024. In March 2023, in connection with the acquisition of Horizon (see Note 4, Acquisitions and divestitures —Acquisition of Horizon Therapeutics plc ), we issued the following series of notes (in millions): Principal Amount 5.25% 2025 Notes $ 2,000 5.507% 2026 Notes 1,500 5.15% 2028 Notes 3,750 5.25% 2030 Notes 2,750 5.25% 2033 Notes 4,250 5.60% 2043 Notes 2,750 5.65% 2053 Notes 4,250 5.75% 2063 Notes 2,750 Total $ 24,000 Also in connection with the acquisition of Horizon, we entered into a $4.0 billion term loan credit agreement in December 2022. In October 2023, in connection with the completion of the acquisition of Horizon, we borrowed $4.0 billion under the term loan credit agreement, of which $2.2 billion was repaid during 2024. As of December 31, 2024, we had $1.8 billion of borrowings outstanding under the term loan credit agreement, which has an interest rate of three-month SOFR plus 1.225% and is due in October 2026. In 2022, we issued $7.0 billion of debt consisting of $750 million of the 3.00% 2029 Notes, $1.25 billion of the 4.05% 2029 Notes, $1.0 billion of the 3.35% 2032 Notes, $750 million of the 4.20% 2033 Notes, $1.0 billion of the 4.20% 2052 Notes, $1.0 billion of the 4.875% 2053 Notes and $1.25 billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued and used to finance eligible projects that met specified criteria to reduce our impact on the environment. Debt extinguishment In 2024, we repurchased an aggregate principal amount of our debt of $875 million, including portions of the 3.15% 2040 Notes, 2.80% 2041 Notes, 3.375% 2050 Notes, 3.00% 2052 Notes, 4.20% 2052 Notes and 4.40% 2062 Notes, for an aggregate cost of $659 million, which resulted in a $215 million gain on extinguishment of debt recorded in Other income (expense), net, in the Consolidated Statements of Income. In 2023, we repurchased an aggregate principal amount of our debt of $881 million, including portions of the 2.00% 2032 Notes, 3.15% 2040 Notes, 2.80% 2041 Notes, 3.375% 2050 Notes, 3.00% 2052 Notes, 4.20% 2052 Notes and 4.40% 2062 Notes, for an aggregate cost of $647 million, which resulted in a $225 million gain on extinguishment of debt recorded in Other income (expense), net, in the Consolidated Statements of Income. In 2022, we repurchased an aggregate principal amount of our debt of $378 million, including portions of the 2.20% 2027 Notes, 1.65% 2028 Notes, 2.00% 2032 Notes, 2.80% 2041 Notes and 3.00% 2052 Notes, for an aggregate cost of $297 million, which resulted in a $78 million gain on extinguishment of debt recorded in Other income (expense), net, in the Consolidated Statements of Income. Debt repayments In 2024, we repaid the full $2.0 billion aggregate principal amount on the term loan due April 2025, $200 million of the aggregate principal amount on the term loan due October 2026 and the full $1.4 billion aggregate principal amount of the 3.625% 2024 Notes. In 2023, we repaid the full $750 million aggregate principal amount of the 2.25% 2023 Notes and the full CHF700 million aggregate principal amount ($704 million upon settlement of the related cross-currency swap) of the 0.41% 2023 Swiss franc Bonds. In 2022, no debt was repaid or redeemed. Interest rate swaps To achieve a desired mix of fixed-rate and floating-rate debt, we enter into interest rate swap contracts that effectively convert fixed-rate interest coupons for certain of our debt instruments to floating SOFR-based coupons over the terms of the respective debt instruments. These interest rate swap contracts qualify and are designated as fair value hedges. For information regarding the terms of these contracts, see Note 19, Derivative instruments. Cross-currency swaps To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts outstanding as of December 31, 2024, effectively convert the interest payments and principal repayments on our 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros and pounds sterling to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 19, Derivative instruments. Cross-currency swap contracts associated with other foreign denominated debt previously outstanding were settled in connection with the repayment of such debt, as discussed above. Shelf registration statement and other facilities As of December 31, 2024, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2024 and 2023, we had no amounts outstanding under our commercial paper program. In the first quarter of 2023, we amended and restated our syndicated, unsecured, revolving credit agreement, under which we may borrow up to $4.0 billion for general corporate purposes, including as a liquidity backstop for our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $1.25 billion with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) SOFR plus 1.01% or (ii) the highest of (A) the administrative agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month SOFR plus 1.1%. As of December 31, 2024 and 2023, no amounts were outstanding under this facility. In February 2023, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time, with terms to be determined at the time of issuance. This shelf registration statement expires in February 2026. Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement and term loan agreement include a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. We were in compliance with all applicable covenants under these arrangements as of December 31, 2024. Contractual maturities of debt obligations The aggregate contractual maturities of our debt obligations as of December 31, 2024, were as follows (in millions): Maturity dates Amounts 2025 $ 3,500 2026 5,922 2027 2,724 2028 4,984 2029 2,876 Thereafter 41,772 Total $ 61,778 Interest costs Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2024, 2023 and 2022, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2024, 2023 and 2022 was $3.3 billion, $2.4 billion and $1.2 billion, respectively.

Stockholders' equity

Stockholders' equity	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Stock repurchase program During the year ended December 31, 2024, we repurchased 0.7 million shares of our common stock for a total cost of $200 million under our stock repurchase program. During the year ended December 31, 2023, we did not repurchase any shares of our common stock under our stock repurchase program. During the year ended December 31, 2022, we repurchased 26.1 million shares of our common stock under our stock repurchase program, consisting primarily of 24.8 million shares received under ASR agreements, for a total cost of $6.3 billion. As of December 31, 2024, $6.8 billion remained available under our stock repurchase program. Dividends Our Board of Directors declared quarterly dividends per share of $2.25, $2.13 and $1.94, which were paid in each of the four quarters of 2024, 2023 and 2022, respectively. Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 10, 2024, the Board of Directors declared a quarterly cash dividend of $2.38 per share of common stock, which will be paid in March 2025, to all stockholders of record as of the close of business on February 14, 2025. Accumulated other comprehensive loss The components of AOCI were as follows (in millions): Foreign currency translation adjustments Cash flow Other AOCI Balance as of December 31, 2021 $ (844) $ 61 $ (13) $ (796) Foreign currency translation adjustments 496 — — 496 Unrealized gains — 84 — 84 Reclassification adjustments to earnings — 2 — 2 Other — — 2 2 Income taxes — (19) — (19) Balance as of December 31, 2022 (348) 128 (11) (231) Foreign currency translation adjustments 50 — — 50 Unrealized gains — 28 — 28 Reclassification adjustments to earnings — (222) — (222) Other — — 42 42 Income taxes — 44 — 44 Balance as of December 31, 2023 (298) (22) 31 (289) Foreign currency translation adjustments (76) — — (76) Unrealized gains — 506 — 506 Reclassification adjustments to earnings — (117) — (117) Other — — (10) (10) Income taxes — (80) — (80) Balance as of December 31, 2024 $ (374) $ 287 $ 21 $ (66) With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to earnings for cash flow hedges were a $105 million expense and a $25 million benefit in 2024, a $6 million expense and a $50 million benefit in 2023 and a $19 million expense and a $0 million benefit in 2022, respectively. Reclassifications out of AOCI and into earnings were as follows (in millions): Years ended December 31, Components of AOCI 2024 2023 2022 Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains $ 192 $ 180 $ 231 Product sales Cross-currency swap contract (losses) gains (75) 42 (233) Other income (expense), net 117 222 (2) Income before income taxes (25) (50) — Provision for income taxes $ 92 $ 172 $ (2) Net income Other In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2024 and 2023, no shares of preferred stock were issued or outstanding.

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 — Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Fair value measurement as of December 31, 2024, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury bills $ — $ 997 $ — $ 997 Money market mutual funds 10,354 — — 10,354 Other short-term interest-bearing securities — 135 — 135 Equity securities 4,188 — — 4,188 Derivatives: Foreign currency forward contracts — 420 — 420 Cross-currency swap contracts — — — — Interest rate swap contracts — — — — Total assets $ 14,542 $ 1,552 $ — $ 16,094 Liabilities: Derivatives: Foreign currency forward contracts $ — $ 8 $ — $ 8 Cross-currency swap contracts — 483 — 483 Interest rate swap contracts — 531 — 531 Contingent consideration obligations — — 106 106 Total liabilities $ — $ 1,022 $ 106 $ 1,128 Fair value measurement as of December 31, 2023, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury bills $ — $ — $ — $ — Money market mutual funds 10,266 — — 10,266 Other short-term interest-bearing securities — 138 — 138 Equity securities 4,514 — — 4,514 Derivatives: Foreign currency forward contracts — 145 — 145 Cross-currency swap contracts — — — — Interest rate swap contracts — — — — Total assets $ 14,780 $ 283 $ — $ 15,063 Liabilities: Derivatives: Foreign currency forward contracts $ — $ 116 $ — $ 116 Cross-currency swap contracts — 405 — 405 Interest rate swap contracts — 571 — 571 Contingent consideration obligations — — 96 96 Total liabilities $ — $ 1,092 $ 96 $ 1,188 Interest-bearing and equity securities The fair values of our U.S. Treasury bills are determined by utilizing third-party pricing services, which obtain pricing data from active market makers and brokers. The fair values of our money market mutual funds and equity investments in publicly traded securities, including our equity investments in BeiGene and Neumora, as of December 31, 2024 and 2023, are based on quoted market prices in active markets, with no valuation adjustment . Derivatives All of our foreign currency forward contracts, cross-currency swap contracts and interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs, as applicable, include foreign currency exchange rates, SOFR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. Certain inputs, when applicable, are at commonly quoted intervals. See Note 19, Derivative instruments. Contingent consideration obligations As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income. Changes in the carrying amounts of contingent consideration obligations were as follows (in millions): Years ended December 31, 2024 2023 2022 Beginning balance $ 96 $ 270 $ 342 Payments (8) (9) (7) Net changes in valuations 18 (165) (65) Ending balance $ 106 $ 96 $ 270 As of December 31, 2024 and 2023, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021, which obligates us to make payments to the former shareholders upon achievement of separate development and regulatory milestones with regard to various R&D programs. In 2023, the development of AMG 340 was terminated, resulting in a decrease of the related contingent consideration liability. During the year ended December 31, 2023, the remeasurement of our contingent consideration liability of $165 million, which was primarily related to the termination of AMG 340, was recognized in Other operating expenses in the Consolidated Statements of Income and included in Other items, net, in the Consolidated Statements of Cash Flows. See Note 13, Goodwill and other intangible assets, for the impact on the related IPR&D asset. Summary of the fair values of other financial instruments Cash equivalents The fair values of cash equivalents are approximated at their carrying values due to the short-term nature of such financial instruments. Borrowings We estimate the fair values of our fixed-rate notes by using Level 2 inputs. As of December 31, 2024 and 2023, the aggregate fair values of our fixed-rate notes were $54.9 billion and $59.2 billion, respectively, and the carrying values of our fixed-rate notes were $58.3 billion and $60.6 billion, respectively. The estimates of the fair values of our term loans approximate their carrying values as of December 31, 2024 and 2023 as these debt instruments bear interest at floating rates. During the years ended December 31, 2024 and 2023, there were no transfers of assets or liabilities between fair value measurement levels, and except with respect to the IPR&D intangible impairment of AMG 340 in 2023 as disclosed in Note 13, Goodwill and other intangible assets, there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.

Derivative instruments

Derivative instruments	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	Derivative instruments The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We have designated certain of our derivatives as cash flow and fair value hedges; we also have derivatives not designated as hedges. We do not use derivatives for speculative trading purposes. Cash flow hedges We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. The foreign currency exchange rate fluctuation exposure associated with cash inflows from our international product sales is partially offset by corresponding cash outflows from our international operating expenses. To further reduce this exposure, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods. As of December 31, 2024, 2023 and 2022, we had outstanding foreign currency forward contracts with aggregate notional amounts of $7.2 billion, $6.6 billion and $6.0 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we record unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings. To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros and pounds sterling and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the terms of the contracts by paying U.S. dollars and receiving euros and pounds sterling. In addition, we will pay U.S. dollars to and receive euros and pounds sterling from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros and pounds sterling to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are recorded in AOCI in the Consolidated Balance Sheets and reclassified to Other income (expense), net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps as of December 31, 2024, were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.6 % In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the terms of the associated debt issuances. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material. The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Years ended December 31, Derivatives in cash flow hedging relationships 2024 2023 2022 Foreign currency forward contracts $ 585 $ (14) $ 308 Cross-currency swap contracts (79) 73 (219) Forward interest rate contracts — (31) (5) Total unrealized gains $ 506 $ 28 $ 84 Fair value hedges To achieve a desired mix of fixed-rate and floating-rate debt, we enter into interest rate swap contracts that qualify for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate SOFR-based coupons over the terms of the related hedge contracts. As of both December 31, 2024 and 2023, we had interest rate swap contracts with an aggregate notional amount of $6.7 billion that hedge certain portions of our long-term debt issuances. During the year ended December 31, 2024, interest rate swap contracts with an aggregate notional amount of $1.4 billion matured in connection with the repayment of the 3.625% 2024 Notes. In addition, we entered into new interest rate swap contracts with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4 billion at an interest rate of SOFR plus 1.8%. As of December 31, 2024 and 2023, the interest rates on the portion of notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): December 31, 2024 2023 Notes Notional amounts Interest rates Notional amounts Interest rates 3.625% 2024 Notes $ — N/A $ 1,400 SOFR + 3.4% 3.125% 2025 Notes 1,000 SOFR + 2.1% 1,000 SOFR + 2.1% 2.60% 2026 Notes 1,250 SOFR + 2.1% 1,250 SOFR + 2.1% 2.45% 2030 Notes 1,000 SOFR + 1.3% 1,000 SOFR + 1.3% 2.30% 2031 Notes 500 SOFR + 1.1% 500 SOFR + 1.1% 5.25% 2033 Notes 1,400 SOFR + 1.8% — N/A 4.663% 2051 Notes 1,500 SOFR + 4.3% 1,500 SOFR + 4.3% Total notional amounts $ 6,650 $ 6,650 N/A = not applicable For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining term of the previously hedged debt. The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) December 31, December 31, Consolidated Balance Sheets locations 2024 2023 2024 2023 Current portion of long-term debt $ 1,045 $ 1,441 $ 45 $ 41 Long-term debt $ 5,152 $ 4,788 $ (388) $ (355) ____________ (1) Current portion of long-term debt includes $56 million and $69 million of carrying value with discontinued hedging relationships as of December 31, 2024 and 2023, respectively. Long-term debt includes $232 million and $288 million of carrying value with discontinued hedging relationships as of December 31, 2024 and 2023, respectively. (2) Current portion of long-term debt includes $56 million and $69 million of hedging adjustments on discontinued hedging relationships as of December 31, 2024 and 2023, respectively. Long-term debt includes $132 million and $188 million of hedging adjustments on discontinued hedging relationships as of December 31, 2024 and 2023, respectively. Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2024 Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 32,026 $ 506 $ (3,155) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 192 $ — $ — Cross-currency swap contracts $ — $ (75) $ — Gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 29 Derivatives designated as hedging instruments $ — $ — $ 40 Year ended December 31, 2023 Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 26,910 $ 2,833 $ (2,875) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 180 $ — $ — Cross-currency swap contracts $ — $ 42 $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (118) Derivatives designated as hedging instruments $ — $ — $ 205 Year ended December 31, 2022 Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,801 $ (814) $ (1,406) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 231 $ — $ — Cross-currency swap contracts $ — $ (233) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 716 Derivatives designated as hedging instruments $ — $ — $ (636) __________ (1) Gains (losses) on hedged items do not exactly offset losses (gains) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2024, we expected to reclassify $170 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. Derivatives not designated as hedges To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2024, 2023 and 2022, the total notional amounts of these foreign currency forward contracts were $148 million, $457 million and $517 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2024, 2023 and 2022. Fair values of derivatives The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities December 31, 2024 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency forward contracts Other current assets/ Other noncurrent assets $ 420 Accrued liabilities/ Other noncurrent liabilities $ 8 Cross-currency swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 483 Interest rate swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 531 Total derivatives designated as hedging instruments 420 1,022 Total derivatives $ 420 $ 1,022 Derivative assets Derivative liabilities December 31, 2023 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency forward contracts Other current assets/ Other noncurrent assets $ 145 Accrued liabilities/ Other noncurrent liabilities $ 116 Cross-currency swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 405 Interest rate swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 571 Total derivatives designated as hedging instruments 145 1,092 Total derivatives $ 145 $ 1,092 For additional information, see Note 18, Fair value measurement. Our derivative contracts that were in liability positions as of December 31, 2024, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change-in-control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change-in-control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur. The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash (used in) provided by financing activities.

Contingencies and commitments

Contingencies and commitments	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors— Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below. Repatha Patent Litigation Patent Disputes in the International Region We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany and Japan. Germany In February 2016, the EPO granted European Patent No. 2,215,124 (the EP’124 Patent) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen’s patent, and each of Lilly, Regeneron Pharmaceuticals, Inc. (Regeneron) and Strawman Ltd. also filed oppositions to Amgen’s patent. In November 2018, the EPO confirmed the validity of Amgen’s EP’124 Patent, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA’s decision, national litigations regarding PRALUENT in Germany are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron filed actions in the Regional Court of Munich seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA’s October 2020 ruling. On May 8, 2024, the Regional Court of Munich issued a preliminary decision and scheduled a further oral hearing on January 15, 2025. On November 13, 2024, the Regional Court of Munich scheduled the next hearing in the matter for May 21, 2025. On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP’004 Patent), which Sanofi Biotechnology SAS licensed from Regeneron. Sanofi Biotechnology SAS is seeking infringement damages and injunctive relief. On May 13, 2024, the Regional Court of Dusseldorf stayed the hearing on Sanofi Biotechnology SAS’ infringement action pending the outcome of Amgen’s Nullity Action against the EP’004 Patent before the German Federal Patent Court. On August 3, 2023, Amgen GmbH filed a Nullity Action before the German Federal Patent Court seeking invalidation of Regeneron’s EP’004 Patent. Regeneron filed a Statement of Defense on November 20, 2023. On February 29, 2024, the German Federal Patent Court scheduled the main hearing for November 25, 2025. Unified Patent Court of the European Union On June 1, 2023, Amgen filed an action before the Munich Local Division of the Unified Patent Court (UPC) against Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A. (collectively, Sanofi-Aventis), and Regeneron alleging that the importation, marketing, sale and use of PRALUENT infringes European Patent 3,666,797 (the EP’797 Patent) seeking an injunction and damages for past infringement. Regeneron filed counterclaims for revocation, but on February 5, 2024, the court transferred the counterclaims to the Central Division of the UPC that is presiding over Sanofi’s revocation action. The Munich Local Division of the UPC scheduled the hearing on our EP’797 Patent infringement action to begin on October 16, 2024. On June 29, 2023, the Central Division of the UPC served Amgen with an action that was filed by Sanofi-Aventis that seeks revocation of the EP’797 Patent. The Central Division of the UPC scheduled a hearing on the revocation action and on July 16, 2024, the Central Division of the UPC rendered its decision, concluding that the patent claims are invalid and revoked the EP’797 Patent. Subsequently, on July 29, 2024, the Munich Local Division of the UPC stayed Amgen’s action against Sanofi-Aventis alleging that the importation, marketing, sale and use of PRALUENT infringes the EP’797 Patent. On September 13, 2024, Amgen filed a Statement of Appeal with the Court of Appeals to the UPC to set aside the Central Division of the UPC’s decision to revoke the EP’797 Patent. The Court of Appeals scheduled oral arguments to take place on May 22, 2025. On January 10, 2024, Sanofi Biotechnologies SAS and Regeneron filed an action against Amgen Inc., Amgen Europe B.V., Amgen N.V., Amgen GmbH, Amgen B.V., Amgen SAS, and Amgen S.R.L before the Dusseldorf Local Division of the UPC, alleging infringement of EP 3,536,712 (the EP’712 Patent), which Sanofi Biotechnology SAS licensed from Regeneron. Sanofi and Regeneron are seeking an injunction against the sale, marketing, use, importation, or storage of Repatha for certain specified uses in Belgium, France, Germany, Italy and the Netherlands. Amgen filed counterclaims for invalidity and non-infringement. On September 25, 2024, Sanofi Biotechnologies SAS and Regeneron filed a brief seeking to expand the ongoing action before the Dusseldorf Local Division of the UPC, alleging that Amgen’s Repatha infringes a newly-issued patent, European Patent No. 4,252,857 (the EP’857 Patent), seeking an injunction against the marketing, use, or importation of Repatha in 18 countries (Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia and Sweden) and damages for past infringement. On December 13, 2024, the Dusseldorf Local Division of the UPC denied Sanofi and Regeneron’s request to extend the complaint and ordered that only the issues of infringement and validity of the EP’712 Patent are to be addressed at an oral hearing scheduled for February 25, 2025. On February 4, 2025, the Dusseldorf Local Division of the UPC formally ordered separation of the EP’857 Patent from the ongoing litigation and ordered Sanofi and Regeneron to file a new Statement of Case by February 28, 2025. European Patent Office On November 16, 2023 and February 29, 2024, Sanofi-Aventis and Regeneron each filed a notice of opposition against Amgen’s EP’797 Patent before the EPO’s Opposition Division. An oral hearing has been scheduled for March 31 to April 4, 2025. On February 29, 2024, Amgen filed a Notice of Opposition and Grounds of Opposition before the EPO against Regeneron’s EP’712 Patent. On March 15, 2024, the EPO notified the parties that the opposition will be accelerated in view of the infringement action pending against Amgen on the EP’712 Patent in the Dusseldorf Local Division of the UPC. An oral hearing has been scheduled for March 11 to 12, 2025. Japan On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.’s appeals making final the High Court’s decisions that PRALUENT infringes Amgen’s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen’s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. On April 15, 2021, the Japan Patent Office dismissed Regeneron’s invalidity trials, and in August 2021 Regeneron appealed the decisions to the High Court. On January 26, 2023, the High Court found Amgen’s patent claims invalid for lacking adequate support and Amgen appealed to the Supreme Court of Japan on March 13, 2023. On September 15, 2023, the Supreme Court of Japan declined to hear Amgen’s appeal. The case was remanded to the Japan Patent Office for further proceedings. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. On September 27, 2023, the Tokyo District Court found Amgen’s patent claims invalid and dismissed Amgen’s lawsuit for damages. Amgen appealed the Tokyo District Court’s decision to the Intellectual Property High Court on December 28, 2023. The Intellectual Property High Court rejected Amgen’s appeal and remanded the case to the Japan Patent Office. Amgen sought amended patent claims before the Japan Patent Office. The Japan Patent Office rejected Amgen’s amended patent claims, and Amgen filed an appeal brief with the Intellectual Property High Court on September 16, 2024 seeking to overturn the Japan Patent Office’s decision. Prolia/XGEVA Biologics Price Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a BLA seeking approval to market and sell a biosimilar version of Amgen’s Prolia and XGEVA products. The complaint asserts infringement of the following 29 patents: U.S. Patent Nos. 7,364,736; 7,427,659; 7,928,205; 8,053,236; 8,460,896; 8,680,248; 9,012,178; 9,228,168; 9,320,816; 9,328,134; 9,359,435; 10,106,829; 10,167,492; 10,227,627; 10,513,723; 10,583,397; 10,822,630; 10,894,972; 11,077,404; 11,098,079; 11,130,980; 11,254,963; 11,299,760; 11,319,568; 11,434,514; 11,459,595; 11,486,883; 11,946,085; and 11,952,605 (collectively, the Asserted Patents against Celltrion). Amgen seeks a judgment from the New Jersey District Court that Celltrion has infringed or will infringe one or more claims of each of the Asserted Patents against Celltrion and based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Celltrion’s proposed denosumab biosimilar before expiration of each of the Asserted Patents against Celltrion found infringed. Amgen also seeks monetary remedies for any past acts of infringement. Celltrion responded to the complaint on July 11, 2024, denying infringement and asserting affirmative defenses including invalidity and non-infringement. On November 25, 2024, the New Jersey District Court issued a Scheduling Order including a hearing on claim construction scheduled for February 14, 2025 and trial beginning on April 7, 2025. On January 23, 2025, the New Jersey District Court issued a consent judgment and injunction finding the Asserted Patents against Celltrion valid, enforceable and infringed by the Celltrion biosimilar denosumab products in the United States. The injunction prohibits Celltrion, its affiliates and any third party acting on behalf of or in active concert with Celltrion from making using, offering to sell, selling or importing Celltrion’s denosumab biosimilar products into the United States before June 1, 2025, except as specifically authorized by a confidential binding settlement term sheet and 35 U.S.C. 271. Specific financial terms remain confidential. The parties’ remaining claims and counterclaims were dismissed with prejudice. Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a BLA seeking approval to market and sell a biosimilar version of Amgen’s Prolia and XGEVA products. The complaint asserts infringement of the following 34 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,058,418; 8,247,210; 8,460,896; 8,680,248; 9,012,178; 9,320,816; 9,328,134; 9,359,435; 9,481,901; 10,106,829; 10,167,492; 10,227,627; 10,421,987; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 10,907,186; 11,098,079; 11,130,980; 11,254,963; 11,292,829; 11,299,760; 11,384,378; 11,427,848; 11,434,514; 11,634,476; 11,685,772; 11,744,950; and 11,946,085 (collectively, the Asserted Patents against Samsung). Amgen seeks a judgment from the New Jersey District Court that Samsung has infringed or will infringe one or more claims of each of the Asserted Patents against Samsung and, based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Samsung’s proposed denosumab biosimilar before expiration of each of the Asserted Patents against Samsung found infringed. Amgen also seeks monetary remedies for any past acts of infringement. Bioepis filed its Answer and Counterclaims in response to the Complaint on October 1, 2024. On November 12, 2024, Bioepis filed an Amended Answer and Counterclaims, and Amgen responded to the Amended Counterclaims on November 26, 2024. Biologics’ response to the Complaint was submitted on October 28, 2024. A trial date has not yet been set. Amgen Inc. et al. v. Fresenius Kabi USA, LLC et al. On October 4, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the Northern District of Illinois (Illinois District Court) against Fresenius Kabi USA, LLC, Fresenius SwissBiosim GmbH, Fresenius Kabi Deutschland, GmbH, and Fresenius Kabi Austria GmbH (collectively Fresenius) based on the submission to the FDA of a BLA seeking approval to market and sell a biosimilar version of Amgen’s Prolia and XGEVA products. The complaint asserts infringement of the following 33 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,053,236; 8,058,418; 8,460,896; 8,680,248; 9,012,178; 9,228,168; 9,320,816; 9,328,134; 9,359,435; 10,106,829; 10,167,492; 10,227,627; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 11,077,404; 11,098,079; 11,130,980; 11,254,963; 11,299,760; 11,319,568; 11,434,514; 11,459,595; 11,744,950; 11,786,866; 11,946,085; 11,952,605; and 12,084,686 (collectively, the Asserted Patents against Fresenius). Amgen seeks a judgment from the Illinois District Court that Fresenius has infringed or will infringe one or more claims of each of the Asserted Patents against Fresenius and based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Fresenius’s proposed denosumab biosimilar before expiration of each of the Asserted Patents against Fresenius found infringed. Amgen also seeks monetary remedies for any past acts of infringement. Fresenius responded to the complaint on December 4, 2024, denying infringement and asserting affirmative defenses including invalidity and non-infringement. On February 6, 2025, the Judicial Panel on Multidistrict Litigation granted Amgen’s November 15, 2024 motion to transfer this case from the Illinois District Court to the New Jersey District Court for coordinated and consolidated pretrial proceedings with the other cases involving Prolia/XGEVA biosimilars pending in the district. Amgen Inc. et al. v. Accord et al. On November 13, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the Eastern District of North Carolina (North Carolina District Court) against Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd. (collectively Accord) based on the submission to the FDA of a BLA seeking approval to market and sell a biosimilar version of Amgen’s Prolia and XGEVA products. The complaint asserts infringement of the following 34 patents: U.S. Patent Nos. 7,364,736; 7,662,930; 7,888,101; 7,928,205; 8,053,236; 8,058,418; 8,460,896; 8,680,248; 9,012,178; 9,133,493; 9,228,168; 9,320,816; 9,328,134; 9,359,435; 9,388,447; 10,106,829; 10,167,492; 10,227,627; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 11,077,404; 11,098,079; 11,130,980; 11,254,963; 11,299,760; 11,319,568; 11,434,514; 11,459,595; 11,946,085; 11,952,605; and 12,084,686 (collectively, the Asserted Patents against Accord). Amgen seeks a judgment from the North Carolina District Court that Accord has infringed or will infringe one or more claims of each of the Asserted Patents against Accord and based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Accord’s proposed denosumab biosimilar before expiration of each of the Asserted Patents against Accord found infringed. Amgen also seeks monetary remedies for any past acts of infringement. Accord responded to the complaint on January 10, 2025, denying infringement and asserting affirmative defenses including invalidity and non-infringement. On February 6, 2025, the Judicial Panel on Multidistrict Litigation granted Amgen’s November 15, 2024 motion to transfer this case from the North Carolina District Court to the New Jersey District Court for coordinated and consolidated pretrial proceedings with the other cases involving Prolia/XGEVA biosimilars pending in the district. On December 30, 2024, the parties jointly filed a stipulation agreeing to a consent injunction, which was subsequently entered by the North Carolina District Court, providing that that the Accord biosimilar products at issue will not be made, used, sold, offered for sale or imported into the United States before October 1, 2025, except as permitted by 35 U.S.C. § 271(e)(1). PAVBLU ™ (aflibercept-ayyh) Patent Litigation On January 10, 2024, Regeneron filed a lawsuit in the U.S. District Court for the Central District of California (California Central District Court) against Amgen alleging infringement of 32 patents listed by Regeneron in the BPCIA exchange. The lawsuit stems from Amgen’s submission of an application under the BPCIA for FDA licensure of PAVBLU as biosimilar to Regeneron’s EYLEA. By its complaint, Regeneron seeks, among other remedies, an injunction prohibiting the commercial manufacture, use, offer for sale or sale in the United States or import into the United States of PAVBLU before the expiration of each of the patents found to be infringed. On January 11, 2024, Regeneron filed a motion with the Judicial Panel on Multidistrict Litigation to transfer this case from the California Central District Court to the U.S. District Court for the Northern District of West Virginia (West Virginia District Court). Amgen responded to Regeneron’s complaint on February 2, 2024, denying infringement and asserting counterclaims seeking a declaratory judgment that the asserted patents are not infringed, invalid, and/or unenforceable. On April 11, 2024, the Judicial Panel on Multidistrict Litigation granted Regeneron’s motion to transfer Regeneron’s patent infringement lawsuit pending against Amgen in the California Central District Court to the West Virginia District Court for coordinated and consolidated pretrial proceedings with the five other cases involving EYLEA biosimilars pending in that district. On June 7, 2024, Regeneron filed a motion for a preliminary injunction to prohibit Amgen from engaging in the manufacture, use, offer for sell or sale within the United States, or importation into the United States, of PAVBLU until resolution of this lawsuit or the entry of a permanent injunction, whichever comes first. Regeneron’s motion focused on U.S. Patent No. 11,084,865, a formulation patent. On September 23, 2024, the West Virginia District Court denied Regeneron’s motion for a preliminary injunction, and Regeneron filed a notice of appeal, a motion to expedite the appeal, and an emergency motion for an injunction pending resolution of the appeal and for an administrative stay with the U.S. Court of Appeals for the Federal Circuit (Federal Circuit Court). On September 25, 2024, the Federal Circuit Court issued an order temporarily enjoining the launch of PAVBLU on an administrative basis while it considered Regeneron’s motion for an injunction pending appeal. On October 22, 2024, the Federal Circuit Court denied Regeneron’s motion for an injunction pending appeal and lifted the temporary injunction that was entered on September 25, 2024. Oral arguments for the appeal were held on January 14, 2025. Antitrust Class Action Sensipar Antitrust Class Actions From February to April 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceuticals USA, Inc. (Teva) alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. Two of those actions were brought in the U.S. District Court for the District of Delaware (Delaware District Court), captioned UFCW Local 1500 Welfare Fund v. Amgen Inc., et al. (February 21, 2019) (Local 1500) and Cesar Castillo, Inc. v. Amgen Inc., et al. (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al. (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (Eastern Pennsylvania District Court), captioned KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar and alleges that the plaintiffs have overpaid for Sensipar as a result of Amgen’s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson Laboratories, Inc. (Watson) and Teva of the parties’ patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys’ fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with Cipla Ltd. v. Amgen Inc. , consolidated and designated as an MDL in the Delaware District Court. On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs’ consolidated class action complaint and the indirect purchaser end payer plaintiffs’ complaint. On December 6, 2019, the plaintiffs responded to Amgen’s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned MSP Recovery Claims v. Amgen Inc., et al. , to the Delaware District Court. On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge’s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs’ objections. On November 30, 2020, the Delaware District Court adopted the Magistrate Judge’s recommendation in part and denied it in part, denying Amgen’s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen’s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs’ offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court’s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints. On February 16, 2021, the plaintiffs in the antitrust class action lawsuit brought on behalf of putative classes of direct or indirect purchasers of Sensipar filed their amended complaints. On March 4, 2021, a stipulation and order regarding the filing of a second amended complaint were filed to add another plaintiff: Teamsters Western Region & Local 177 Health Care Fund. On March 17, 2021, a defendant, MSP Recovery Claims, Series LLC, filed its notice of voluntary dismissal. On March 30, 2021, the remaining defendants, including Amgen, filed their motions to dismiss the second amended complaint. On April 27, 2021, plaintiffs filed their oppositions to defendants’ (including Amgen’s) motion to dismiss, and defendants’ reply was filed on May 25, 2021. A hearing on defendants’ motion to dismiss was held in the Delaware District Court on July 13, 2021. On March 11, 2022, the Delaware District Court granted defendants’ (including Amgen’s) motion to dismiss except as to the reverse payment claim and various state law claims from ten of the states in which plaintiffs reside. On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal. The plaintiffs did not oppose Amgen’s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs’ motion on June 10, 2022, and reply briefs were filed on June 24, 2022. On February 16, 2023, the Delaware District Court denied Amgen’s motion for interlocutory appeal. On March 2, 2023, Amgen filed a motion for reargument, which the Delaware District Court denied while also certifying a question regarding whether the current judge has the authority to certify a question decided by a predecessor judge. On April 17, 2023, Amgen filed a petition with the U.S. Court of Appeals for the Third Circuit (Third Circuit Court), seeking a grant of our request for interlocutory appeal of the certified question as well as the Delaware District Court’s denial of our motion to dismiss the reverse payment claim. Amgen’s response to the class action complaints is due 30 days after resolution or denial of the interlocutory appeal. On June 26, 2023, the Third Circuit Court entered an order granting defendants’ (including Amgen’s) petition for interlocutory appeal and denying plaintiffs’ cross-petition. The questions certified are whether (1) the statute for interlocutory decisions authorizes a district court judge to certify for interlocutory appeal an order issued in the same case by a predecessor district court judge; and (2) the settlement of a patent infringement claim that involves the forgiveness of damages associated with that patent’s alleged infringement, on its own or combined with an acceleration clause, constitutes a reverse payment. On July 3, 2023, Amgen and Teva Pharmaceuticals USA, Inc. filed a notice of appeal, and on October 17, 2023, Amgen submitted its initial brief in its appeal before the Third Circuit Court. On January 12, 2024, Amgen reached an agreement in principle to settle with the putative class of indirect purchasers of Sensipar. On February 17, 2024, Amgen and the indirect purchasers filed a stipulation in the Delaware District Court to dismiss the indirect purchasers’ claims. On February 22, 2024, Amgen and the indirect purchasers filed a stipulation in the Third Circuit Court dismissing the portion of the Third Circuit Court’s appeal relating to the claims of the indirect purchasers. Amgen and the direct purchasers filed a stipulation on April 12, 2024 in the Delaware District Court, dismissing with prejudice the direct purchasers’ claims that were at issue in the appeal and seeking entry of final judgment in Amgen’s favor. On April 15, 2024, the Delaware District Court entered an order pursuant to the stipulation and closed the case. On May 14, 2024, the putative class of direct purchasers of Sensipar appealed the claims that were dismissed with prejudice by the Delaware District Court. On November 12, 2024, Amgen settled with the putative class of direct purchasers of Sensipar, and the remaining claims were dismissed on November 29, 2024. Regeneron Pharmaceuticals, Inc. Antitrust Action On May 27, 2022, Regeneron filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen’s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payers and PBMs have harmed the sales of its product PRALUENT and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen’s initial responsive pleading, a motion to dismiss, was filed on August 1, 2022. On August 11, 2022, Amgen moved to stay the case pending the ultimate decision on the merits of the ongoing patent litigation between Amgen and Regeneron in Amgen Inc., et al. v. Sanofi, et al. On January 6, 2023, the Delaware District Court heard oral argument on the motion to stay and the motion to dismiss. On February 10, 2023, the Delaware District Court denied Amgen’s motion to stay this action, and on March 21, 2023, the Delaware District Court denied Amgen’s motion to dismiss the complaint. On August 28, 2023, Regeneron filed its amended complaint, and on September 20, 2023, Amgen filed a counterclaim, alleging Regeneron’s own anticompetitive conduct with respect to formulary position for Regeneron’s drug, PRALUENT, at CVS. Trial was originally scheduled to begin on November 12, 2024, but has been rescheduled for May 2, 2025. On November 20, 2024 the Delaware District Court heard Amgen’s motion for summary judgment and the parties’ motions to exclude expert testimony, and the motions are currently under submission. CareFirst of Maryland Antitrust Class Action On August 6, 2024, CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., and Care

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II AMGEN INC. VALUATION AND QUALIFYING ACCOUNTS Years ended December 31, 2024, 2023 and 2022 (In millions) Allowance for doubtful accounts Balance Additions Other Deductions Balance 2024 $ 28 $ 13 $ — $ (3) $ 38 2023 $ 22 $ 6 $ — $ — $ 28 2022 $ 26 $ — $ — $ (4) $ 22

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net income	$ 4,090	$ 6,717	$ 6,552

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Amgen has a multi-layered and iterative approach towards assessing, identifying, managing and mitigating risks from cybersecurity threats. The Amgen Technology & Medical Organizations (ATMOS) function is designed to support our productivity, innovation and outreach globally through the quality delivery of information systems, solutions and services for our business and operations. The ATMOS function has a Cybersecurity & Digital Trust (CDT) team that assesses and reduces cybersecurity exposure, including by providing employees with training and resources to identify potential cybersecurity threats and implementing information technology security practices. The CDT team also monitors for cybersecurity threat activity and seeks to mitigate the impact from cybersecurity incidents by deploying information security engineers, system architects, analysts and cybersecurity specialists to provide monitoring, reporting and management of cybersecurity incidents. To evaluate the progress of its activities, our ATMOS function uses various industry and regulatory frameworks as guides to assess the state of the Company’s cybersecurity program maturity and controls, including our organizational, people, physical and technological controls. The CDT team also conducts reviews and evaluations of our cybersecurity resilience program with Amgen’s Cybersecurity & Digital Trust Governance Council (which includes leaders from CDT, Worldwide Compliance and Business Ethics, Regulatory Affairs, Operations, R&D, Global Commercial Operations, Corporate Audit, Law and Business Development functions). Our cybersecurity risk management program is considered by and integrated into our Company-wide Enterprise Risk Management program and shares common methodologies, reporting channels and governance processes that apply across the Enterprise Risk Management program to that of other enterprise level risks (such as product development, safety and surveillance, financial and intellectual property risks). Regular evaluations are conducted of the greatest risks to our business and their underlying risk drivers as well as the associated mitigation activities, maturity and controls. This program is overseen by our Executive Vice President and Chief Financial Officer and guided by the Enterprise Risk Council, a cross-functional group of the Company’s business leaders representing key business functions that is co-chaired by our Chief Audit Executive. The results of the enterprise risk evaluations and the status and operation of the Enterprise Risk Management program are presented to our Board of Directors, which oversees the Company’s enterprise-level risks. Further, our corporate audit function is responsible for assessing risk and testing whether, and the extent to which, our information security policies and practices are being implemented effectively within our business and by third party providers. Findings from such reports and related corrective action plans are shared with our CDT team, Company leadership, and the Audit Committee and Corporate Responsibility and Compliance Committee (CRCC) of our Board of Directors. In addition to leveraging the Company’s own information technology resources, our Incident Response and Cyber Threat Intelligence teams engage, as needed, third-party cybersecurity risk assessors and consultants to assist in recognizing threats, identifying security vulnerabilities and evaluating the impact of cybersecurity attacks and incidents when they occur. On a biennial basis, our ATMOS also engages external third-party experts to assess the Company’s cybersecurity control maturity across the organization and develops plans to address such experts’ recommendations. Our CDT function has processes to oversee and identify the risks of cybersecurity threats associated with third-party service providers and monitors and works to mitigate the impact of cybersecurity incidents encountered by our third-party service providers. Upon becoming aware of cybersecurity incidents encountered by our third-party service providers, the CDT function’s Incident Response and Cyber Threat Intelligence teams are deployed to evaluate and mitigate the impact of such incidents on our business. In connection with our adoption of artificial intelligence (AI) tools in our business, including AI tools customized for our business and a variety of Amgen-built tools for use across applications, the Company established an AI Governance Council composed of cross-functional leadership that oversees the safe adoption of third-party AI services, including by establishing guardrails to reduce risks and allocating resources to provide staff training on the proper use of AI and responsible AI practices. The AI Governance Council is co-sponsored by our Chief Compliance Officer and Senior Vice President, Artificial Intelligence & Data. Despite our layered controls and cybersecurity efforts, the Company and its third-party vendors have experienced cyberattacks and information security vulnerabilities, and while such incidents have not had a material adverse effect on the Company, there can be no assurance that future cybersecurity attacks or incidents would not result in a material adverse effect on our business strategy, results of operations or financial condition. For examples of such matters and a discussion of the risks that we face, see Item 1A. Risk Factors— A breakdown of our information technology systems, cyberattack or information security breach could significantly compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation. However, we have not identified risk from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our cybersecurity risk management program is considered by and integrated into our Company-wide Enterprise Risk Management program and shares common methodologies, reporting channels and governance processes that apply across the Enterprise Risk Management program to that of other enterprise level risks (such as product development, safety and surveillance, financial and intellectual property risks). Regular evaluations are conducted of the greatest risks to our business and their underlying risk drivers as well as the associated mitigation activities, maturity and controls. This program is overseen by our Executive Vice President and Chief Financial Officer and guided by the Enterprise Risk Council, a cross-functional group of the Company’s business leaders representing key business functions that is co-chaired by our Chief Audit Executive. The results of the enterprise risk evaluations and the status and operation of the Enterprise Risk Management program are presented to our Board of Directors, which oversees the Company’s enterprise-level risks.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board of Directors oversees an enterprise-wide approach to risk management, including risks related to information systems and cybersecurity, and each Board committee has primary risk oversight responsibilities aligned with its areas of focus. At each regular meeting of the Board, the Board receives and considers reports from each of its committees, and such reports provide additional detail on significant risk management issues as appropriate, including cybersecurity. The CRCC is the committee that has primary oversight responsibility for the Company’s information systems and management of cybersecurity and receives reports from our Senior Vice President and Chief Information Officer (CIO) and Chief Information Security Officer (CISO) that includes reviews of our information systems strategy, technology investments, cybersecurity risks and incidents, and third-party risk management, as well as an annual evaluation of the Company’s cybersecurity status. The Board’s Audit Committee has oversight responsibility of our internal controls, assurances and financial risks. The Audit Committee is provided with copies of materials presented to our CRCC by our CIO and CISO and receives reports from our CIO regarding topics including integration or implementation of new financial systems and key controls and governance designed to address cybersecurity risks associated with the use of such new financial systems.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our management team, including our CIO and CISO, supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which may include briefings from internal information security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information systems environment.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee is provided with copies of materials presented to our CRCC by our CIO and CISO and receives reports from our CIO regarding topics including integration or implementation of new financial systems and key controls and governance designed to address cybersecurity risks associated with the use of such new financial systems. Our management team, including our CIO and CISO, supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which may include briefings from internal information security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information systems environment.
Cybersecurity Risk Role of Management [Text Block]	Our management team, including our CIO and CISO, supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which may include briefings from internal information security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information systems environment. Our CISO, who heads our CDT team and is accountable for the Company’s cybersecurity risk management program, joined the Company’s information systems organization in 2016, is a Certified Information Systems Security Professional and is certified in risk and information systems control. Previously, our CISO served in both leadership and operational positions as a cybersecurity professional in the U.S. government and was a cybersecurity consultant, providing a wide range of cybersecurity services to various U.S. government agencies and departments. Our CISO is overseen by our CIO, who has 27 years of experience in information systems (including over 14 years at the Company and more than 6 years as a senior technology executive outside of Amgen), and holds a Computer Information Systems B.S. and an Information Technology Management MBA. Our Executive Vice President and Chief Technology Officer (CTO) leads our ATMOS function and oversees our CIO. As leaders of the Technology and CDT functions within ATMOS, respectively, the Company’s CIO and CISO are informed about and monitor significant cybersecurity threats and incidents through the Company’s internal cybersecurity reporting structure. Our CDT team is responsible for monitoring and detecting cybersecurity threats and incidents. Our CDT team, overseen by our CISO, is also responsible for the mitigation and remediation of cybersecurity incidents. When members of the CDT team detect a cybersecurity threat or incident or are made aware of a cybersecurity incident encountered by a third-party service provider, the discovery is communicated to the Incident Response team, which includes our CISO and other senior members of the CDT function. The Incident Response team evaluates the severity of the cybersecurity threat or incident and shares its findings with our CISO. Our CISO and/or his senior team leaders, in addition to our CIO and CTO, also provide regular reports to executives leading our Finance, Compliance, Law and Human Resources functions on potentially significant cybersecurity incidents and the progress made towards mitigation and remediation of those incidents. These leaders oversee reporting to our CRCC and Audit Committee, and reporting of such cybersecurity incidents is included in the course of regular meetings of such committees. Additionally, in appropriate circumstances, reporting of potentially significant cybersecurity incidents is made directly to the leaders of our CRCC and Audit Committee or directly to the Board of Directors outside of their regular meeting schedule. Further, in support of our internal controls, our CISO also reviews cybersecurity matters and trends with our Accounting and Law functions at least on a quarterly basis.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our CISO, who heads our CDT team and is accountable for the Company’s cybersecurity risk management program, joined the Company’s information systems organization in 2016, is a Certified Information Systems Security Professional and is certified in risk and information systems control. Previously, our CISO served in both leadership and operational positions as a cybersecurity professional in the U.S. government and was a cybersecurity consultant, providing a wide range of cybersecurity services to various U.S. government agencies and departments.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our CISO is overseen by our CIO, who has 27 years of experience in information systems (including over 14 years at the Company and more than 6 years as a senior technology executive outside of Amgen), and holds a Computer Information Systems B.S. and an Information Technology Management MBA.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Additionally, in appropriate circumstances, reporting of potentially significant cybersecurity incidents is made directly to the leaders of our CRCC and Audit Committee or directly to the Board of Directors outside of their regular meeting schedule. Further, in support of our internal controls, our CISO also reviews cybersecurity matters and trends with our Accounting and Law functions at least on a quarterly basis.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its consolidated subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate our business in one operating segment: human therapeutics. See Note 2, Segment and other information.
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Revenues	Revenues Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers. Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&A expense in the Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the R&D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.
Research and development costs	Research and development costs R&D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs; and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 9, Collaborations.
Selling, general and administrative costs	Selling, general and administrative costs SG&A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $987 million, $647 million and $841 million during the years ended December 31, 2024, 2023 and 2022, respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 9, Collaborations.
Leases	Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.
Stock-based compensation	Stock-based compensation We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 5, Stock-based compensation.
Income taxes	Income taxes We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 7, Income taxes.
Acquisitions	Acquisitions We first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&D projects, and liabilities assumed are recorded in our consolidated financial statements at their respective fair values as of the acquisition date. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination, including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to our acquisition, are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 4, Acquisitions and divestitures, and Note 18, Fair value measurement.
Cash equivalents	Cash equivalents We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.
Interest-bearing securities	Interest-bearing securities We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company’s investments that are available for current operations. See Note 10, Investments, and Note 18, Fair value measurement.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 11, Inventories.
Derivatives	Derivatives We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 18, Fair value measurement, and Note 19, Derivative instruments.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 12, Property, plant and equipment.
Goodwill and other intangible assets	Goodwill and other intangible assets Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets’ estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 13, Goodwill and other intangible assets. The fair values of IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors’ products could result in partial or full impairment of the related intangible assets. We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 13, Goodwill and other intangible assets.
Contingencies	Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 20, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Foreign currency translation	Foreign currency translation The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries’ earnings are translated into U.S. dollars by using average exchange rates.
Equity investments	Equity investments Marketable and nonmarketable equity securities Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other income (expense), net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost less impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other income (expense), net, in the Consolidated Statements of Income.
Equity method investments	Equity method investments Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income (expense), net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value. For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income (expense), net, in the Consolidated Statements of Income. Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income (expense), net, in the Consolidated Statements of Income.
Recently adopted accounting pronouncements and Recent accounting pronouncements not yet adopted	Recently adopted accounting pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and additional interim segment reporting disclosures, including for companies with a single reportable segment. The standard is effective for public business entities such as Amgen for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, with retrospective application required for all prior periods presented. We adopted this standard in fiscal year 2024, which resulted in incremental segment disclosures. See Note 2, Segment and other information. Recent accounting pronouncements not yet adopted In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve income tax disclosure requirements by requiring more detailed information on several income tax disclosures, such as enhancing disclosure of income taxes paid and requiring disaggregation of the effective income tax rate reconciliation. The standard is effective for public business entities such as Amgen for annual periods beginning after December 15, 2024. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. We are currently evaluating the impact of adopting this standard on our consolidated financial statements and related disclosures. In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve disclosures about a public business entity’s expenses by requiring disaggregated disclosures of certain types of expenses, including purchases of inventory, employee compensation, depreciation, intangible amortization and depletion, as applicable, for each income statement caption that includes those expenses. In addition, the standard will require entities to define and disclose total selling expenses. The standard is effective for public business entities such as Amgen for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. We are currently evaluating the impact of adopting this standard on our consolidated financial statements and related disclosures.

Segment and other information (

Segment and other information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following table provides segment revenues, significant segment expenses, other segment items, reported segment net income and a reconciliation of segment net income to the Company’s total consolidated net income for the years ended December 31, 2024, 2023 and 2022 (in millions): Years ended December 31, 2024 2023 2022 Revenues: Product sales $ 32,026 $ 26,910 $ 24,801 Other revenues 1,398 1,280 1,522 Total revenues 33,424 28,190 26,323 Less: Manufacturing cost of sales (1)(2) 11,118 7,347 5,776 Profit share and royalties in cost of sales (1) 1,740 1,104 630 Research and development (1) 5,964 4,784 4,434 Sales and marketing (1) 4,713 3,784 3,736 General and administrative (1) 2,383 2,395 1,678 Other segment items (3) 262 (743) 777 Equity in (income) loss of equity method investments (10) 14 667 Interest income (510) (1,225) (127) Interest expense, net 3,155 2,875 1,406 Provision for income taxes 519 1,138 794 Segment net income 4,090 6,717 6,552 Reconciliation of profit or loss: Adjustments and reconciling items — — — Consolidated net income $ 4,090 $ 6,717 $ 6,552 ____________ (1) During the years ended December 31, 2024, 2023 and 2022, we recognized amortization expense on our intangible assets of $4.8 billion, $3.2 billion and $2.6 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. In addition, during the years ended December 31, 2024, 2023 and 2022, we recognized depreciation and ROU asset amortization expense of $805 million, $824 million and $818 million, respectively. (2) During the years ended December 31, 2024, 2023 and 2022, manufacturing cost of sales included amortization of step-up to fair value of inventory acquired in business combinations of $2.4 billion, $656 million and $30 million, respectively. (3) Other segment items included in Segment net income primarily consists of: (i) fair value adjustments on equity securities (see Note 10, Investments) and (ii) net impairment charges on intangible assets (see Note 13, Goodwill and other intangible assets). For the year ended December 31, 2023, other segment items also included expenses related to our restructuring plan that was both initiated and substantially completed in 2023. For the year ended December 31, 2022, other segment items also included a loss on the divestiture of Gensenta (see Note 4, Acquisitions and divestitures).

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue by Product and by Geographic Area	Revenues were as follows (in millions): Year ended December 31, 2024 Year ended December 31, 2023 Year ended December 31, 2022 U.S. ROW Total U.S. ROW Total U.S. ROW Total Prolia $ 2,885 $ 1,489 $ 4,374 $ 2,733 $ 1,315 $ 4,048 $ 2,465 $ 1,163 $ 3,628 ENBREL 3,288 28 3,316 3,650 47 3,697 4,044 73 4,117 XGEVA 1,507 718 2,225 1,527 585 2,112 1,480 534 2,014 Repatha 1,139 1,083 2,222 793 842 1,635 608 688 1,296 Otezla 1,699 427 2,126 1,777 411 2,188 1,886 402 2,288 TEPEZZA (1) 1,835 16 1,851 441 7 448 — — — EVENITY 1,131 432 1,563 809 351 1,160 533 254 787 KYPROLIS 948 555 1,503 921 482 1,403 850 397 1,247 Nplate 970 486 1,456 996 481 1,477 848 459 1,307 Aranesp 386 956 1,342 452 910 1,362 521 900 1,421 BLINCYTO 800 416 1,216 566 295 861 336 247 583 KRYSTEXXA (1) 1,185 — 1,185 272 — 272 — — — Vectibix 519 526 1,045 461 523 984 396 497 893 TEZSPIRE 972 — 972 567 — 567 170 — 170 Other products (2) 4,037 1,593 5,630 3,307 1,389 4,696 3,606 1,444 5,050 Total product sales (3) 23,301 8,725 32,026 19,272 7,638 26,910 17,743 7,058 24,801 Other revenues 562 836 1,398 534 746 1,280 852 670 1,522 Total revenues $ 23,863 $ 9,561 $ 33,424 $ 19,806 $ 8,384 $ 28,190 $ 18,595 $ 7,728 $ 26,323 ____________ (1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date. (2) Consists of product sales of our non-principal products. (3) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2024, 2023 and 2022.
Schedule of Revenues Earned from Major Customers	For the year ended December 31, 2024, on a combined basis, these customers accounted for 77% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions): Years ended December 31, 2024 2023 2022 McKesson Corporation: Gross product sales $ 22,173 $ 19,035 $ 17,305 % of total gross revenues 33 % 33 % 35 % Cencora, Inc.: Gross product sales $ 18,387 $ 16,625 $ 15,443 % of total gross revenues 27 % 29 % 31 % Cardinal Health, Inc.: Gross product sales $ 11,278 $ 9,775 $ 8,319 % of total gross revenues 17 % 17 % 16 %

Acquisitions and divestitures (

Acquisitions and divestitures (Tables)	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement-period adjustments (in millions): Cash and cash equivalents $ 681 Inventories 5,014 Property, plant and equipment, net 318 Finite-lived intangible assets—developed-product-technology rights 19,590 IPR&D 1,060 Goodwill 3,136 Deferred tax asset 795 Deferred tax liability (2,488) Other assets and liabilities, net (273) Total assets acquired, net of liabilities assumed $ 27,833 The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement-period adjustments (in millions): Cash and cash equivalents $ 86 Marketable securities 235 Inventories 41 Finite-lived intangible assets—developed-product-technology rights 3,499 Goodwill 649 Other liabilities, net (83) Deferred tax liability, net (502) Total assets acquired, net of liabilities assumed $ 3,925
Schedule of Supplemental Pro Forma Financial Information	The following table presents the unaudited supplemental pro forma results of a hypothetical combined Amgen and Horizon entity for the years ended December 31, 2023 and 2022, as if the acquisition of Horizon had occurred on January 1, 2022 (in millions): Years ended December 31, 2023 2022 Total revenues $ 30,969 $ 29,964 Net income $ 5,383 $ 2,381

Stock-based compensation (Table

Stock-based compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Components of Stock-based Compensation Expense	The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions): Years ended December 31, 2024 2023 2022 RSUs $ 351 $ 309 $ 227 Performance units 133 121 132 Stock options 46 43 42 Total stock-based compensation expense, pretax 530 473 401 Tax benefit from stock-based compensation expense (114) (102) (86) Total stock-based compensation expense, net of tax $ 416 $ 371 $ 315
Schedule of RSUs	The following table summarizes information regarding our RSUs: Year ended December 31, 2024 Units Weighted-average Balance nonvested as of December 31, 2023 3.9 $ 246.43 Granted 1.5 $ 301.36 Vested (1.6) $ 250.80 Forfeited (0.3) $ 267.28 Balance nonvested as of December 31, 2024 3.5 $ 265.07
Schedule of Stock Option Assumptions	The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows: Years ended December 31, 2024 2023 2022 Closing price of our common stock on grant date $ 300.30 $ 235.97 $ 230.92 Expected volatility (average of implied and historical volatility) 26.9 % 23.3 % 24.5 % Expected life (in years) 5.7 5.7 5.7 Risk-free interest rate 4.4 % 3.4 % 2.8 % Expected dividend yield 3.2 % 3.5 % 3.3 % Fair value of stock options granted $ 69.34 $ 41.86 $ 42.43
Schedule of Stock Options	The following table summarizes information regarding our stock options: Year ended December 31, 2024 Options Weighted- Weighted- Aggregate Balance unexercised as of December 31, 2023 5.9 $ 213.90 Granted 0.8 $ 300.32 Exercised (0.6) $ 201.22 Expired/forfeited (0.2) $ 248.94 Balance unexercised as of December 31, 2024 5.9 $ 225.84 6.3 $ 236 Vested or expected to vest as of December 31, 2024 5.7 $ 224.34 6.2 $ 234 Exercisable as of December 31, 2024 3.1 $ 202.02 4.6 $ 182
Schedule of Weighted-Average Assumptions	The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows: Years ended December 31, 2024 2023 2022 Closing price of our common stock on grant date $ 300.30 $ 235.97 $ 230.92 Volatility 22.1 % 21.6 % 28.1 % Risk-free interest rate 4.6 % 3.7 % 0.3 % Fair value of units granted $ 321.61 $ 252.49 $ 247.48

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Income before income taxes included the following (in millions): Years ended December 31, 2024 2023 2022 Domestic $ 4,040 $ 4,047 $ 3,026 Foreign 569 3,808 4,320 Total income before income taxes $ 4,609 $ 7,855 $ 7,346
Schedule of Provision for Income Taxes	The provision for income taxes included the following (in millions): Years ended December 31, 2024 2023 2022 Current provision: Federal $ 965 $ 1,524 $ 1,721 State 33 43 44 Foreign 759 786 304 Total current provision 1,757 2,353 2,069 Deferred benefit: Federal (860) (1,124) (1,185) State (18) (25) (27) Foreign (360) (66) (63) Total deferred benefit (1,238) (1,215) (1,275) Total provision for income taxes $ 519 $ 1,138 $ 794
Schedule of Deferred Tax Assets and Liabilities	Significant components of our deferred tax assets and liabilities were as follows (in millions): December 31, 2024 2023 Deferred income tax assets: NOL and credit carryforwards $ 1,352 $ 1,465 Accrued expenses 693 668 Capitalized research and development expenses 1,762 1,333 Investments 1 — Expenses capitalized for tax 200 210 Earnings of foreign subsidiaries 1,496 1,260 Stock-based compensation 130 159 Other 361 416 Total deferred income tax assets 5,995 5,511 Valuation allowance (1,019) (957) Net deferred income tax assets 4,976 4,554 Deferred income tax liabilities: Acquired intangible assets (2,573) (3,028) Debt (264) (268) Fixed assets (143) (140) Fair value of acquired inventory (114) (349) Investments — (99) Other (244) (224) Total deferred income tax liabilities (3,338) (4,108) Total deferred income taxes, net $ 1,638 $ 446
Schedule of Reconciliation of Total Gross Amounts of UTBs	The reconciliations of the total gross amounts of UTBs were as follows (in millions): Years ended December 31, 2024 2023 2022 Beginning balance $ 4,012 $ 3,770 $ 3,546 Additions based on tax positions related to the current year 188 196 151 Additions based on tax positions related to prior years 9 56 90 Reductions for tax positions of prior years (12) — (14) Reductions for expiration of statute of limitations (9) (4) (3) Settlements (4) (6) — Ending balance $ 4,184 $ 4,012 $ 3,770
Schedule of Reconciliation of Federal Statutory Tax Rate	The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows: Years ended December 31, 2024 2023 2022 Federal statutory tax rate 21.0 % 21.0 % 21.0 % Foreign earnings (5.8) % (5.1) % (5.6) % Foreign-derived intangible income (3.0) % (1.3) % (1.3) % Credits, Puerto Rico excise tax — % 0.3 % (2.8) % Interest on uncertain tax positions 4.2 % 2.6 % 1.9 % Credits, primarily federal R&D (5.4) % (3.5) % (2.0) % Other, net 0.3 % 0.5 % (0.4) % Effective tax rate 11.3 % 14.5 % 10.8 %

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of Computation for Basic and Diluted Earnings per Share	The computations for basic and diluted EPS were as follows (in millions, except per-share data): Years ended December 31, 2024 2023 2022 Income (Numerator): Net income for basic and diluted EPS $ 4,090 $ 6,717 $ 6,552 Shares (Denominator): Weighted-average shares for basic EPS 537 535 538 Effect of dilutive securities 4 3 3 Weighted-average shares for diluted EPS 541 538 541 Basic EPS $ 7.62 $ 12.56 $ 12.18 Diluted EPS $ 7.56 $ 12.49 $ 12.11

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-For-Sale Investments	The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are classified as available for sale, by type of security were as follows (in millions): Types of securities as of December 31, 2024 Amortized Gross Gross Fair U.S. Treasury bills $ 997 $ — $ — $ 997 Money market mutual funds 10,354 — — 10,354 Other short-term interest-bearing securities 135 — — 135 Total available-for-sale investments $ 11,486 $ — $ — $ 11,486 Types of securities as of December 31, 2023 Amortized Gross Gross Fair U.S. Treasury bills $ — $ — $ — $ — Money market mutual funds 10,266 — — 10,266 Other short-term interest-bearing securities 138 — — 138 Total available-for-sale investments $ 10,404 $ — $ — $ 10,404
Schedule of Fair Values by Classification	The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions): December 31, Consolidated Balance Sheets locations 2024 2023 Cash and cash equivalents $ 11,486 $ 10,404 Total available-for-sale investments $ 11,486 $ 10,404

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following (in millions): December 31, 2024 2023 Raw materials $ 818 $ 993 Work in process 4,120 5,747 Finished goods 2,060 2,778 Total inventories (1) $ 6,998 $ 9,518 ____________ (1) The decrease to Inventories during the year ended December 31, 2024, was primarily due to amortization of the inventory step-up to fair value related to acquired inventory from the Horizon acquisition. See Note 4, Acquisitions and divestitures.

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consisted of the following (dollar amounts in millions): December 31, Useful life (in years) 2024 2023 Land — $ 346 $ 339 Buildings and improvements 10-40 4,803 4,507 Manufacturing equipment 8-12 3,291 3,220 Laboratory equipment 8-12 1,345 1,346 Fixed equipment 12 2,592 2,526 Capitalized software 3-5 1,442 1,320 Other 5-10 1,059 941 Construction in progress — 2,053 1,550 Property, plant and equipment, gross 16,931 15,749 Less accumulated depreciation and amortization (10,388) (9,808) Property, plant and equipment, net $ 6,543 $ 5,941
Schedule of Property, Plant and Equipment by Geographic Area	Certain geographic information with respect to property, plant and equipment, net, was as follows (in millions): December 31, 2024 2023 U.S. $ 4,156 $ 3,658 Puerto Rico 1,174 1,148 ROW 1,213 1,135 Total property, plant and equipment, net $ 6,543 $ 5,941

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amounts of goodwill were as follows (in millions): December 31, 2024 2023 Beginning balance $ 18,629 $ 15,529 Changes to goodwill resulting from acquisitions, net (1) 25 3,089 Foreign currency translation adjustments (17) 11 Ending balance $ 18,637 $ 18,629 ____________ (1) For 2024, changes to Goodwill consisted of measurement-period adjustments related to our Horizon acquisition. For 2023, changes to Goodwill primarily consisted of goodwill resulting from our Horizon acquisition. See Note 4, Acquisitions and divestitures.
Schedule of Other Intangible Assets	Other intangible assets consisted of the following (in millions): December 31, 2024 2023 Gross Accumulated Other intangible Gross Accumulated Other intangible Finite-lived intangible assets: Developed-product-technology rights $ 48,611 $ (22,594) $ 26,017 $ 48,631 $ (18,049) $ 30,582 Licensing rights 3,875 (3,392) 483 3,865 (3,265) 600 Marketing-related rights 1,202 (1,202) — 1,339 (1,264) 75 R&D technology rights 1,374 (1,235) 139 1,394 (1,228) 166 Total finite-lived intangible assets 55,062 (28,423) 26,639 55,229 (23,806) 31,423 Indefinite-lived intangible assets: In-process research and development 1,060 — 1,060 1,218 — 1,218 Total other intangible assets $ 56,122 $ (28,423) $ 27,699 $ 56,447 $ (23,806) $ 32,641

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Operating Leases	The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions): December 31, Consolidated Balance Sheets locations 2024 2023 Assets: Other noncurrent assets $ 557 $ 651 Liabilities: Accrued liabilities $ 107 $ 119 Other noncurrent liabilities 673 691 Total lease liabilities $ 780 $ 810 The components of net lease costs were as follows (in millions): Years ended December 31, Lease costs 2024 2023 2022 Operating (1) $ 219 $ 208 $ 218 Sublease income (17) (28) (32) Total net lease costs $ 202 $ 180 $ 186 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2024, 2023 and 2022. The weighted-average remaining lease terms and weighted-average discount rates were as follows: December 31, 2024 2023 Weighted-average remaining lease term (in years) 9.3 9.7 Weighted-average discount rate 3.7 % 3.6 % Cash and noncash information related to our leases was as follows (in millions): Years ended December 31, 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 156 $ 182 $ 171 ROU assets obtained in exchange for lease obligations: Operating leases $ 126 $ 245 $ 191
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities as of December 31, 2024, were as follows (in millions): Maturity dates Amounts 2025 $ 110 2026 129 2027 112 2028 91 2029 73 Thereafter 426 Total lease payments (1) 941 Less imputed interest (161) Present value of lease liabilities $ 780 ____________ (1) Includes future rental commitments for abandoned leases of $51 million. We expect to receive total future rental income of $54 million related to noncancellable subleases for abandoned facilities.

Other current assets and accr_2

Other current assets and accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Schedule of Other Current Assets	Other current assets consisted of the following (in millions): December 31, 2024 2023 Prepaid expenses $ 2,139 $ 1,647 Corporate partner receivables 521 502 Tax receivables 198 172 Other 419 281 Total other current assets $ 3,277 $ 2,602
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in millions): December 31, 2024 2023 Sales deductions $ 8,405 $ 7,271 Income taxes payable 2,583 1,664 Employee compensation and benefits 1,329 1,381 Dividends payable 1,278 1,205 Accrued interest payable 867 936 Other 3,179 2,902 Total accrued liabilities $ 17,641 $ 15,359

Financing arrangements (Tables)

Financing arrangements (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Borrowings	Our borrowings consisted of the following (in millions): December 31, 2024 2023 3.625% notes due 2024 (3.625% 2024 Notes) $ — $ 1,400 1.90% notes due 2025 (1.90% 2025 Notes) 500 500 5.25% notes due 2025 (5.25% 2025 Notes) 2,000 2,000 Term loan due April 2025 — 2,000 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 777 828 5.507% notes due 2026 (5.507% 2026 Notes) 1,500 1,500 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 Term loan due October 2026 1,800 2,000 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 595 605 2.20% notes due 2027 (2.20% 2027 Notes) 1,724 1,724 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 5.15% notes due 2028 (5.15% 2028 Notes) 3,750 3,750 1.65% notes due in 2028 (1.65% 2028 Notes) 1,234 1,234 3.00% notes due 2029 (3.00% 2029 Notes) 750 750 4.05% notes due 2029 (4.05% 2029 Notes) 1,250 1,250 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 876 892 2.45% notes due 2030 (2.45% 2030 Notes) 1,250 1,250 5.25% notes due 2030 (5.25% 2030 Notes) 2,750 2,750 2.30% notes due 2031 (2.30% 2031 Notes) 1,250 1,250 2.00% notes due 2032 (2.00% 2032 Notes) 1,001 1,001 3.35% notes due 2032 (3.35% 2032 Notes) 1,000 1,000 4.20% notes due 2033 (4.20% 2033 Notes) 750 750 5.25% notes due 2033 (5.25% 2033 Notes) 4,250 4,250 6.375% notes due 2037 (6.375% 2037 Notes) 478 478 6.90% notes due 2038 (6.90% 2038 Notes) 254 254 6.40% notes due 2039 (6.40% 2039 Notes) 333 333 3.15% notes due 2040 (3.15% 2040 Notes) 1,668 1,803 5.75% notes due 2040 (5.75% 2040 Notes) 373 373 2.80% notes due 2041 (2.80% 2041 Notes) 776 949 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 729 729 5.65% notes due 2042 (5.65% 2042 Notes) 415 415 5.60% notes due 2043 (5.60% 2043 Notes) 2,750 2,750 5.375% notes due 2043 (5.375% 2043 Notes) 185 185 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 3.375% notes due 2050 (3.375% 2050 Notes) 1,764 2,132 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 3.00% notes due 2052 (3.00% 2052 Notes) 890 999 4.20% notes due 2052 (4.20% 2052 Notes) 895 950 4.875% notes due 2053 (4.875% 2053 Notes) 1,000 1,000 5.65% notes due 2053 (5.65% 2053 Notes) 4,250 4,250 2.77% notes due 2053 (2.77% 2053 Notes) 940 940 December 31, 2024 2023 4.40% notes due 2062 (4.40% 2062 Notes) 1,165 1,200 5.75% notes due 2063 (5.75% 2063 Notes) 2,750 2,750 Other notes due 2097 100 100 Total principal amount of debt 61,778 66,330 Unamortized bond discounts, premiums and issuance costs, net (1,360) (1,420) Fair value adjustments (343) (314) Other 24 17 Total carrying value of debt 60,099 64,613 Less current portion (3,550) (1,443) Total long-term debt $ 56,549 $ 63,170 In March 2023, in connection with the acquisition of Horizon (see Note 4, Acquisitions and divestitures —Acquisition of Horizon Therapeutics plc ), we issued the following series of notes (in millions): Principal Amount 5.25% 2025 Notes $ 2,000 5.507% 2026 Notes 1,500 5.15% 2028 Notes 3,750 5.25% 2030 Notes 2,750 5.25% 2033 Notes 4,250 5.60% 2043 Notes 2,750 5.65% 2053 Notes 4,250 5.75% 2063 Notes 2,750 Total $ 24,000
Schedule of Aggregate Contractual Maturities of Debt Obligations	The aggregate contractual maturities of our debt obligations as of December 31, 2024, were as follows (in millions): Maturity dates Amounts 2025 $ 3,500 2026 5,922 2027 2,724 2028 4,984 2029 2,876 Thereafter 41,772 Total $ 61,778

Stockholders' equity (Tables)

Stockholders' equity (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of Components of AOCI	The components of AOCI were as follows (in millions): Foreign currency translation adjustments Cash flow Other AOCI Balance as of December 31, 2021 $ (844) $ 61 $ (13) $ (796) Foreign currency translation adjustments 496 — — 496 Unrealized gains — 84 — 84 Reclassification adjustments to earnings — 2 — 2 Other — — 2 2 Income taxes — (19) — (19) Balance as of December 31, 2022 (348) 128 (11) (231) Foreign currency translation adjustments 50 — — 50 Unrealized gains — 28 — 28 Reclassification adjustments to earnings — (222) — (222) Other — — 42 42 Income taxes — 44 — 44 Balance as of December 31, 2023 (298) (22) 31 (289) Foreign currency translation adjustments (76) — — (76) Unrealized gains — 506 — 506 Reclassification adjustments to earnings — (117) — (117) Other — — (10) (10) Income taxes — (80) — (80) Balance as of December 31, 2024 $ (374) $ 287 $ 21 $ (66)
Schedule of Reclassifications Out of AOCI	Reclassifications out of AOCI and into earnings were as follows (in millions): Years ended December 31, Components of AOCI 2024 2023 2022 Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains $ 192 $ 180 $ 231 Product sales Cross-currency swap contract (losses) gains (75) 42 (233) Other income (expense), net 117 222 (2) Income before income taxes (25) (50) — Provision for income taxes $ 92 $ 172 $ (2) Net income

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities on Recurring Basis	The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Fair value measurement as of December 31, 2024, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury bills $ — $ 997 $ — $ 997 Money market mutual funds 10,354 — — 10,354 Other short-term interest-bearing securities — 135 — 135 Equity securities 4,188 — — 4,188 Derivatives: Foreign currency forward contracts — 420 — 420 Cross-currency swap contracts — — — — Interest rate swap contracts — — — — Total assets $ 14,542 $ 1,552 $ — $ 16,094 Liabilities: Derivatives: Foreign currency forward contracts $ — $ 8 $ — $ 8 Cross-currency swap contracts — 483 — 483 Interest rate swap contracts — 531 — 531 Contingent consideration obligations — — 106 106 Total liabilities $ — $ 1,022 $ 106 $ 1,128 Fair value measurement as of December 31, 2023, using: Quoted prices in Significant other Significant Total Assets: Available-for-sale securities: U.S. Treasury bills $ — $ — $ — $ — Money market mutual funds 10,266 — — 10,266 Other short-term interest-bearing securities — 138 — 138 Equity securities 4,514 — — 4,514 Derivatives: Foreign currency forward contracts — 145 — 145 Cross-currency swap contracts — — — — Interest rate swap contracts — — — — Total assets $ 14,780 $ 283 $ — $ 15,063 Liabilities: Derivatives: Foreign currency forward contracts $ — $ 116 $ — $ 116 Cross-currency swap contracts — 405 — 405 Interest rate swap contracts — 571 — 571 Contingent consideration obligations — — 96 96 Total liabilities $ — $ 1,092 $ 96 $ 1,188
Contingent Consideration Obligations	Changes in the carrying amounts of contingent consideration obligations were as follows (in millions): Years ended December 31, 2024 2023 2022 Beginning balance $ 96 $ 270 $ 342 Payments (8) (9) (7) Net changes in valuations 18 (165) (65) Ending balance $ 106 $ 96 $ 270

Derivative instruments (Tables)

Derivative instruments (Tables)	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Cross-Currency Swaps	The notional amounts and interest rates of our cross-currency swaps as of December 31, 2024, were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.6 %
Schedule of Unrealized Gains and Losses Recognized in AOCI	The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Years ended December 31, Derivatives in cash flow hedging relationships 2024 2023 2022 Foreign currency forward contracts $ 585 $ (14) $ 308 Cross-currency swap contracts (79) 73 (219) Forward interest rate contracts — (31) (5) Total unrealized gains $ 506 $ 28 $ 84
Schedule of Interest Rate Derivatives	As of December 31, 2024 and 2023, the interest rates on the portion of notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): December 31, 2024 2023 Notes Notional amounts Interest rates Notional amounts Interest rates 3.625% 2024 Notes $ — N/A $ 1,400 SOFR + 3.4% 3.125% 2025 Notes 1,000 SOFR + 2.1% 1,000 SOFR + 2.1% 2.60% 2026 Notes 1,250 SOFR + 2.1% 1,250 SOFR + 2.1% 2.45% 2030 Notes 1,000 SOFR + 1.3% 1,000 SOFR + 1.3% 2.30% 2031 Notes 500 SOFR + 1.1% 500 SOFR + 1.1% 5.25% 2033 Notes 1,400 SOFR + 1.8% — N/A 4.663% 2051 Notes 1,500 SOFR + 4.3% 1,500 SOFR + 4.3% Total notional amounts $ 6,650 $ 6,650 N/A = not applicable
Schedule of Hedged Liabilities and Cumulative Amount	The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) December 31, December 31, Consolidated Balance Sheets locations 2024 2023 2024 2023 Current portion of long-term debt $ 1,045 $ 1,441 $ 45 $ 41 Long-term debt $ 5,152 $ 4,788 $ (388) $ (355) ____________ (1) Current portion of long-term debt includes $56 million and $69 million of carrying value with discontinued hedging relationships as of December 31, 2024 and 2023, respectively. Long-term debt includes $232 million and $288 million of carrying value with discontinued hedging relationships as of December 31, 2024 and 2023, respectively. (2) Current portion of long-term debt includes $56 million and $69 million of hedging adjustments on discontinued hedging relationships as of December 31, 2024 and 2023, respectively. Long-term debt includes $132 million and $188 million of hedging adjustments on discontinued hedging relationships as of December 31, 2024 and 2023, respectively.
Schedule of Income and Expense Line Items	The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2024 Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 32,026 $ 506 $ (3,155) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 192 $ — $ — Cross-currency swap contracts $ — $ (75) $ — Gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 29 Derivatives designated as hedging instruments $ — $ — $ 40 Year ended December 31, 2023 Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 26,910 $ 2,833 $ (2,875) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 180 $ — $ — Cross-currency swap contracts $ — $ 42 $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (118) Derivatives designated as hedging instruments $ — $ — $ 205 Year ended December 31, 2022 Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,801 $ (814) $ (1,406) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 231 $ — $ — Cross-currency swap contracts $ — $ (233) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 716 Derivatives designated as hedging instruments $ — $ — $ (636) __________ (1)
Schedule of Fair Value of Derivatives	The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities December 31, 2024 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency forward contracts Other current assets/ Other noncurrent assets $ 420 Accrued liabilities/ Other noncurrent liabilities $ 8 Cross-currency swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 483 Interest rate swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 531 Total derivatives designated as hedging instruments 420 1,022 Total derivatives $ 420 $ 1,022 Derivative assets Derivative liabilities December 31, 2023 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency forward contracts Other current assets/ Other noncurrent assets $ 145 Accrued liabilities/ Other noncurrent liabilities $ 116 Cross-currency swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 405 Interest rate swap contracts Other current assets/ Other noncurrent assets — Accrued liabilities/ Other noncurrent liabilities 571 Total derivatives designated as hedging instruments 145 1,092 Total derivatives $ 145 $ 1,092 For additional information, see Note 18, Fair value measurement.

Summary of significant accoun_3

Summary of significant accounting policies - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of operating segments | segment	1
Sales return provisions as a percentage of gross product sales (less than)	1%
Advertising cost | $	$ 987	$ 647	$ 841
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue payment term (in days)	30 days
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue payment term (in days)	120 days

Segment and other information -

Segment and other information - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Segment and other information_2

Segment and other information - Schedule of Reconciliation of Segment Net Income to Consolidated Net Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting, Asset Reconciling Item [Line Items]
Total revenues	$ 33,424	$ 28,190	$ 26,323
Manufacturing cost of sales	12,858	8,451	6,406
Equity in (income) loss of equity method investments	(10)	11	891
Interest income	(510)	(1,200)	(127)
Interest expense, net	3,155	2,875	1,406
Provision for income taxes	519	1,138	794
Net income	4,090	6,717	6,552
Amortization expense of intangible assets	4,800	3,200	2,600
Depreciation and right-of-use asset amortization expense	805	824	818
Fair Value Adjustment to Inventory
Segment Reporting, Asset Reconciling Item [Line Items]
Amortization of step-up to fair value of inventory acquired	2,400	656	30
Operating Segments
Segment Reporting, Asset Reconciling Item [Line Items]
Total revenues	33,424	28,190	26,323
Manufacturing cost of sales	11,118	7,347	5,776
Profit share and royalties in cost of sales	1,740	1,104	630
Research and development	5,964	4,784	4,434
Sales and marketing	4,713	3,784	3,736
General and administrative	2,383	2,395	1,678
Other segment items	262	(743)	777
Equity in (income) loss of equity method investments	(10)	14	667
Interest income	(510)	(1,225)	(127)
Interest expense, net	3,155	2,875	1,406
Provision for income taxes	519	1,138	794
Net income	4,090	6,717	6,552
Adjustments and reconciling items
Segment Reporting, Asset Reconciling Item [Line Items]
Net income	0	0	0
Product sales
Segment Reporting, Asset Reconciling Item [Line Items]
Total revenues	32,026	26,910	24,801
Other revenues
Segment Reporting, Asset Reconciling Item [Line Items]
Total revenues	$ 1,398	$ 1,280	$ 1,522

Revenues - Narrative (Details)

Revenues - Narrative (Details) - segment	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Concentration Risk [Line Items]
Number of operating segments	1
Percentage of net trade receivables due from customers located outside the United States, primarily in Europe	26%	22%
Three Customers | Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	70%	75%

Revenues - Schedule of Disaggre

Revenues - Schedule of Disaggregation of Revenue by Product and by Geographic Area (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 33,424	$ 28,190	$ 26,323
U.S.
Disaggregation of Revenue [Line Items]
Total revenues	23,863	19,806	18,595
ROW
Disaggregation of Revenue [Line Items]
Total revenues	9,561	8,384	7,728
Prolia
Disaggregation of Revenue [Line Items]
Total revenues	4,374	4,048	3,628
Prolia | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	2,885	2,733	2,465
Prolia | ROW
Disaggregation of Revenue [Line Items]
Total revenues	1,489	1,315	1,163
ENBREL
Disaggregation of Revenue [Line Items]
Total revenues	3,316	3,697	4,117
ENBREL | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	3,288	3,650	4,044
ENBREL | ROW
Disaggregation of Revenue [Line Items]
Total revenues	28	47	73
XGEVA
Disaggregation of Revenue [Line Items]
Total revenues	2,225	2,112	2,014
XGEVA | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	1,507	1,527	1,480
XGEVA | ROW
Disaggregation of Revenue [Line Items]
Total revenues	718	585	534
Repatha
Disaggregation of Revenue [Line Items]
Total revenues	2,222	1,635	1,296
Repatha | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	1,139	793	608
Repatha | ROW
Disaggregation of Revenue [Line Items]
Total revenues	1,083	842	688
Otezla
Disaggregation of Revenue [Line Items]
Total revenues	2,126	2,188	2,288
Otezla | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	1,699	1,777	1,886
Otezla | ROW
Disaggregation of Revenue [Line Items]
Total revenues	427	411	402
TEPEZZA
Disaggregation of Revenue [Line Items]
Total revenues	1,851	448	0
TEPEZZA | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	1,835	441	0
TEPEZZA | ROW
Disaggregation of Revenue [Line Items]
Total revenues	16	7	0
EVENITY
Disaggregation of Revenue [Line Items]
Total revenues	1,563	1,160	787
EVENITY | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	1,131	809	533
EVENITY | ROW
Disaggregation of Revenue [Line Items]
Total revenues	432	351	254
KYPROLIS
Disaggregation of Revenue [Line Items]
Total revenues	1,503	1,403	1,247
KYPROLIS | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	948	921	850
KYPROLIS | ROW
Disaggregation of Revenue [Line Items]
Total revenues	555	482	397
Nplate
Disaggregation of Revenue [Line Items]
Total revenues	1,456	1,477	1,307
Nplate | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	970	996	848
Nplate | ROW
Disaggregation of Revenue [Line Items]
Total revenues	486	481	459
Aranesp
Disaggregation of Revenue [Line Items]
Total revenues	1,342	1,362	1,421
Aranesp | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	386	452	521
Aranesp | ROW
Disaggregation of Revenue [Line Items]
Total revenues	956	910	900
BLINCYTO
Disaggregation of Revenue [Line Items]
Total revenues	1,216	861	583
BLINCYTO | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	800	566	336
BLINCYTO | ROW
Disaggregation of Revenue [Line Items]
Total revenues	416	295	247
KRYSTEXXA
Disaggregation of Revenue [Line Items]
Total revenues	1,185	272	0
KRYSTEXXA | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	1,185	272	0
KRYSTEXXA | ROW
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0
Vectibix
Disaggregation of Revenue [Line Items]
Total revenues	1,045	984	893
Vectibix | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	519	461	396
Vectibix | ROW
Disaggregation of Revenue [Line Items]
Total revenues	526	523	497
TEZSPIRE
Disaggregation of Revenue [Line Items]
Total revenues	972	567	170
TEZSPIRE | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	972	567	170
TEZSPIRE | ROW
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0
Other products
Disaggregation of Revenue [Line Items]
Total revenues	5,630	4,696	5,050
Other products | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	4,037	3,307	3,606
Other products | ROW
Disaggregation of Revenue [Line Items]
Total revenues	1,593	1,389	1,444
Product sales
Disaggregation of Revenue [Line Items]
Total revenues	32,026	26,910	24,801
Product sales | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	23,301	19,272	17,743
Product sales | ROW
Disaggregation of Revenue [Line Items]
Total revenues	8,725	7,638	7,058
Other revenues
Disaggregation of Revenue [Line Items]
Total revenues	1,398	1,280	1,522
Other revenues | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	562	534	852
Other revenues | ROW
Disaggregation of Revenue [Line Items]
Total revenues	$ 836	$ 746	$ 670

Revenues - Schedule of Revenues

Revenues - Schedule of Revenues Earned from Major Customers (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue, Major Customer [Line Items]
Gross product sales	$ 33,424	$ 28,190	$ 26,323
Product sales
Revenue, Major Customer [Line Items]
Gross product sales	$ 32,026	26,910	24,801
Three Customers | Revenue Benchmark | Customer Concentration Risk
Revenue, Major Customer [Line Items]
Concentration risk, percentage	77%
McKesson Corporation | Product sales
Revenue, Major Customer [Line Items]
Gross product sales	$ 22,173	$ 19,035	$ 17,305
McKesson Corporation | Product sales | Revenue Benchmark | Customer Concentration Risk
Revenue, Major Customer [Line Items]
Concentration risk, percentage	33%	33%	35%
Cencora, Inc. | Product sales
Revenue, Major Customer [Line Items]
Gross product sales	$ 18,387	$ 16,625	$ 15,443
Cencora, Inc. | Product sales | Revenue Benchmark | Customer Concentration Risk
Revenue, Major Customer [Line Items]
Concentration risk, percentage	27%	29%	31%
Cardinal Health, Inc. | Product sales
Revenue, Major Customer [Line Items]
Gross product sales	$ 11,278	$ 9,775	$ 8,319
Cardinal Health, Inc. | Product sales | Revenue Benchmark | Customer Concentration Risk
Revenue, Major Customer [Line Items]
Concentration risk, percentage	17%	17%	16%

Acquisitions and divestitures -

Acquisitions and divestitures - Acquisition of Horizon Therapeutics plc (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended	12 Months Ended
	Oct. 06, 2023	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill		$ 18,629	$ 18,637	$ 15,529
Horizon Therapeutics
Business Acquisition [Line Items]
Acquisition price per share (in usd per share)	$ 116.50
Consideration transferred	$ 27,800
Goodwill increase			$ 25
Cash purchase price	26,700
Consideration transferred for vested and outstanding awards	523
Consideration transferred for replacement awards	180
Liabilities incurred	$ 382
Replacement equity awards issued (in shares)	1.7
Inventories	$ 5,014
Business combination, turnover period of inventory acquired (in months)	27 months
Deferred tax liability	$ 2,488
Deferred tax asset	795
Goodwill	3,136
Acquisition related costs		487
Share-based compensation acceleration expense		167
Acquisition related transaction costs		$ 320
Horizon Therapeutics | Developed-product-technology rights
Business Acquisition [Line Items]
Estimated fair value	$ 20,700
Weighted average period of amortization (in years)	10 years

Acquisitions and divestitures_2

Acquisitions and divestitures - Schedule of Business Acquisitions, by Acquisition (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Oct. 06, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 18,637	$ 18,629		$ 15,529
Horizon Therapeutics
Business Acquisition [Line Items]
Cash and cash equivalents			$ 681
Inventories			5,014
Property, plant and equipment, net			318
IPR&D			1,060
Goodwill			3,136
Deferred tax asset			795
Deferred tax liability			(2,488)
Other assets and liabilities, net			(273)
Total assets acquired, net of liabilities assumed			27,833
Horizon Therapeutics | Developed-product-technology rights
Business Acquisition [Line Items]
Finite-lived intangible assets—developed-product-technology rights			$ 19,590

Acquisitions and divestitures_3

Acquisitions and divestitures - Schedule of Supplemental Pro Forma Financial Information (Details) - Horizon Therapeutics - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Total revenues	$ 30,969	$ 29,964
Net income	$ 5,383	$ 2,381

Acquisitions and divestitures_4

Acquisitions and divestitures - Acquisition of ChemoCentryx, Inc. Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Oct. 20, 2022	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill		$ 18,629	$ 18,637	$ 15,529
ChemoCentryx, Inc.
Business Acquisition [Line Items]
Acquisition price per share (in usd per share)	$ 52
Business asset acquisition, consideration transferred	$ 3,900
Goodwill, net decrease		$ 18
Cash purchase price	3,700
Business acquisition, cash consideration paid to equity holders for pre-acquisition services	181
Inventories	$ 41
Business combination, turnover period of inventory acquired (in months)	13 months
Deferred tax liability	$ (502)
Goodwill	649
ChemoCentryx, Inc. | Developed-product-technology rights
Business Acquisition [Line Items]
Finite-lived intangible assets	$ 3,499
Weighted average period of amortization (in years)	11 years

Acquisitions and divestitures_5

Acquisitions and divestitures - Schedule of Total Consideration for ChemoCentryx Inc (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Oct. 20, 2022
Business Acquisition [Line Items]
Goodwill	$ 18,637	$ 18,629	$ 15,529
ChemoCentryx, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents				$ 86
Marketable securities				235
Inventories				41
Goodwill				649
Other liabilities, net				(83)
Deferred tax liability, net				(502)
Total assets acquired, net of liabilities assumed				3,925
ChemoCentryx, Inc. | Developed-product-technology rights
Business Acquisition [Line Items]
Finite-lived intangible assets—developed-product-technology rights				$ 3,499

Acquisitions and divestitures_6

Acquisitions and divestitures - Divestiture of Gensenta (Details) - USD ($) $ in Millions		12 Months Ended
	Nov. 02, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Proceeds from divestiture of businesses	$ 130
Divested assets	$ 86
Foreign currency translation, loss on divestiture of a business		$ 615
Other general expense
Business Acquisition [Line Items]
Loss on divestiture		$ 567

Stock-based compensation - Narr

Stock-based compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount by which the pool of available shares will be reduced for each stock option granted (in shares)		1
The amount of common stock available under the plan for future grants and/or issuances (in shares)		59,000,000
Total unrecognized compensation cost related to nonvested awards		$ 510
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized (in years)		1 year 9 months 18 days
Period over which the grants of equity instruments vest (in years)		3 years
Number of common shares issued for each performance unit earned (in shares)		1	1	1
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted (in shares)		1.9
Number of shares added back for tax withholding on full value awards (in shares)		1.9
Awards accelerated and settled	$ 42
Weighted average grant date fair value, granted (in usd per share)		$ 301.36	$ 237.70	$ 234.47
Total fair value of units that vested during the year		$ 401	$ 309	$ 192
Units outstanding (in shares)	3,900,000	3,500,000	3,900,000
Weighted-average grant date fair value (in usd per share)	$ 246.43	$ 265.07	$ 246.43
Units granted (in shares)		1,500,000
Units, forfeited (in shares)		300,000
Weighted average grant date fair value, forfeited (in usd per share)		$ 267.28
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of stock options from date of grant (in years)		10 years
Total intrinsic value of stock options exercised during the year		$ 70	$ 33	67
Actual tax benefits realized from tax deductions from option exercises		$ 15	$ 7	$ 14
Performance units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted (in shares)		1.9
Number of shares added back for tax withholding on full value awards (in shares)		1.9
Weighted average grant date fair value, granted (in usd per share)		$ 321.61	$ 252.49	$ 247.48
Total fair value of units that vested during the year		$ 182	$ 109	$ 150
Total unrecognized compensation cost related to nonvested awards		$ 87
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized (in years)		1 year
Units outstanding (in shares)	1,700,000	1,400,000	1,700,000
Weighted-average grant date fair value (in usd per share)	$ 251.41	$ 263.86	$ 251.41
Units granted (in shares)		300,000
Units, forfeited (in shares)		100,000
Weighted average grant date fair value, forfeited (in usd per share)		$ 261.03

Stock-based compensation - Sche

Stock-based compensation - Schedule of Components of Stock-based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	$ 530	$ 473	$ 401
Tax benefit from stock-based compensation expense	(114)	(102)	(86)
Total stock-based compensation expense, net of tax	416	371	315
RSUs
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	351	309	227
Performance units
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	133	121	132
Stock options
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	$ 46	$ 43	$ 42

Stock-based compensation - Sc_2

Stock-based compensation - Schedule of RSUs (Details) - RSUs - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Units
Balance nonvested at beginning of period (in shares)	3.9
Granted (in shares)	1.5
Vested (in shares)	(1.6)
Forfeited (in shares)	(0.3)
Balance nonvested at end of period (in shares)	3.5	3.9
Weighted-average grant date fair value
Balance nonvested at beginning of period (in usd per share)	$ 246.43
Granted (in usd per share)	301.36	$ 237.70	$ 234.47
Vested (in usd per share)	250.80
Forfeited (in usd per share)	267.28
Balance nonvested at end of period (in usd per share)	$ 265.07	$ 246.43

Stock-based compensation - Sc_3

Stock-based compensation - Schedule of Stock Option Assumptions (Details) - Stock options - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of our common stock on grant date (in usd per share)	$ 300.30	$ 235.97	$ 230.92
Volatility	26.90%	23.30%	24.50%
Expected life (in years)	5 years 8 months 12 days	5 years 8 months 12 days	5 years 8 months 12 days
Risk-free interest rate	4.40%	3.40%	2.80%
Expected dividend yield	3.20%	3.50%	3.30%
Fair value of stock options granted (in usd per share)	$ 69.34	$ 41.86	$ 42.43

Stock-based compensation - Sc_4

Stock-based compensation - Schedule of Stock Options (Details) - Stock options $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Options
Balance unexercised at beginning of period (in shares) | shares	5.9
Granted (in shares) | shares	0.8
Exercised (in shares) | shares	(0.6)
Expired/forfeited (in shares) | shares	(0.2)
Balance unexercised at end of period (in shares) | shares	5.9
Vested or expected to vest (in shares) | shares	5.7
Exercisable (in shares) | shares	3.1
Weighted- average exercise price
Balance unexercised at beginning of period (in usd per share) | $ / shares	$ 213.90
Granted (in usd per share) | $ / shares	300.32
Exercised (in usd per share) | $ / shares	201.22
Expired/forfeited (in usd per share) | $ / shares	248.94
Balance unexercised at end of period (in shares) | $ / shares	225.84
Weighted-average exercise price, vested or expected to vest (in usd per share) | $ / shares	224.34
Weighted-average exercise price, exercisable (in usd per share) | $ / shares	$ 202.02
Stock options information [Abstract]
Weighted-average remaining contractual life (in years), unexercised	6 years 3 months 18 days
Weighted-average remaining contractual life (in years), vested or expected to vest	6 years 2 months 12 days
Weighted-average remaining contractual life (in years), exercisable	4 years 7 months 6 days
Aggregate intrinsic value, unexercised | $	$ 236
Aggregate intrinsic value, vested or expected to vest | $	234
Aggregate intrinsic value, exercisable | $	$ 182

Stock-based compensation - Sc_5

Stock-based compensation - Schedule of Weighted-Average Assumptions (Details) - Performance units - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]
Closing price of our common stock on grant date (in usd per share)	$ 300.30	$ 235.97	$ 230.92
Volatility	22.10%	21.60%	28.10%
Risk-free interest rate	4.60%	3.70%	0.30%
Fair value of units granted (in usd per share)	$ 321.61	$ 252.49	$ 247.48

Defined contribution plan - Nar

Defined contribution plan - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Defined contribution plan expenses	$ 375	$ 311	$ 243

Income taxes - Schedule of Inco

Income taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Domestic	$ 4,040	$ 4,047	$ 3,026
Foreign	569	3,808	4,320
Total income before income taxes	$ 4,609	$ 7,855	$ 7,346

Income taxes - Schedule of Prov

Income taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current provision:
Federal	$ 965	$ 1,524	$ 1,721
State	33	43	44
Foreign	759	786	304
Total current provision	1,757	2,353	2,069
Deferred benefit:
Federal	(860)	(1,124)	(1,185)
State	(18)	(25)	(27)
Foreign	(360)	(66)	(63)
Total deferred benefit	(1,238)	(1,215)	(1,275)
Total provision for income taxes	$ 519	$ 1,138	$ 794

Income taxes - Schedule of Defe

Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Deferred income tax assets:
NOL and credit carryforwards	$ 1,352	$ 1,465
Accrued expenses	693	668
Capitalized research and development expenses	1,762	1,333
Investments	1	0
Expenses capitalized for tax	200	210
Earnings of foreign subsidiaries	1,496	1,260
Stock-based compensation	130	159
Other	361	416
Total deferred income tax assets	5,995	5,511
Valuation allowance	(1,019)	(957)
Net deferred income tax assets	4,976	4,554
Deferred income tax liabilities:
Acquired intangible assets	(2,573)	(3,028)
Debt	(264)	(268)
Fixed assets	(143)	(140)
Fair value of acquired inventory	(114)	(349)
Investments	0	(99)
Other	(244)	(224)
Total deferred income tax liabilities	(3,338)	(4,108)
Total deferred income taxes, net	$ 1,638	$ 446

Income taxes - Narrative (Detai

Income taxes - Narrative (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 19, 2022 case	Apr. 28, 2022 USD ($)	Jul. 31, 2021 USD ($) notice
Tax Credit Carryforward [Line Items]
Interest and penalties related to unrecognized tax benefits recognized in income tax provision		$ 282,000,000	$ 287,000,000	$ 189,000,000
Accrued interest and penalties associated with unrecognized tax benefits		1,600,000,000	1,400,000,000
Income taxes paid		2,900,000,000	$ 3,400,000,000	$ 2,400,000,000
Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
IRS advance deposit	$ 800,000,000
Federal
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes		195,000,000
NOL carryforwards available to reduce income taxes		239,000,000
NOL carryforwards, valuation allowance		0
NOLs with no valuation allowance and no expiration		201,000,000
Number of notices on proposed additional tax | notice							2
Number of notices consolidated in court | case					2
Federal | Expiration in tax years between 2025 and 2044
Tax Credit Carryforward [Line Items]
Tax credit carryforwards, valuation allowance		17,000,000
Federal | Tax Years 2010-2012
Tax Credit Carryforward [Line Items]
Proposed additional income tax							$ 3,600,000,000
Repatriation tax on proposed additional tax							$ 900,000,000
Federal | Tax Years 2013-2015
Tax Credit Carryforward [Line Items]
Proposed additional income tax						$ 5,100,000,000
Penalties on proposed additional income tax						2,000,000,000
Repatriation tax on proposed additional tax						$ 2,200,000,000
State
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes		1,200,000,000
Tax credit carryforwards, valuation allowance		1,100,000,000
NOL carryforwards available to reduce income taxes		957,000,000
NOL carryforwards, valuation allowance		822,000,000
Foreign
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes		83,000,000
Tax credit carryforwards, valuation allowance		53,000,000
NOL carryforwards available to reduce income taxes		1,100,000,000
NOL carryforwards, valuation allowance		164,000,000
NOLs with no valuation allowance and no expiration		160,000,000
Foreign | Operating losses that expire between 2025 and 2033
Tax Credit Carryforward [Line Items]
NOL carryforwards, valuation allowance		$ 0

Income taxes - Schedule of Reco

Income taxes - Schedule of Reconciliation of Total Gross Amounts of UTBs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]
Beginning balance	$ 4,012	$ 3,770	$ 3,546
Additions based on tax positions related to the current year	188	196	151
Additions based on tax positions related to prior years	9	56	90
Reductions for tax positions of prior years	(12)	0	(14)
Reductions for expiration of statute of limitations	(9)	(4)	(3)
Settlements	(4)	(6)	0
Ending balance	$ 4,184	$ 4,012	$ 3,770

Income taxes - Schedule of Re_2

Income taxes - Schedule of Reconciliation of Federal Statutory Tax Rate (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21%	21%	21%
Foreign earnings	(5.80%)	(5.10%)	(5.60%)
Foreign-derived intangible income	(3.00%)	(1.30%)	(1.30%)
Credits, Puerto Rico excise tax	0%	0.30%	(2.80%)
Interest on uncertain tax positions	4.20%	2.60%	1.90%
Credits, primarily federal R&D	(5.40%)	(3.50%)	(2.00%)
Other, net	0.30%	0.50%	(0.40%)
Effective tax rate	11.30%	14.50%	10.80%

Earnings per share - Schedule o

Earnings per share - Schedule of Computation for Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income (Numerator):
Net income for basic and diluted EPS	$ 4,090	$ 6,717	$ 6,552
Shares (Denominator):
Weighted-average shares for basic EPS (in shares)	537	535	538
Effect of dilutive securities (in shares)	4	3	3
Weighted-average shares for diluted EPS (in shares)	541	538	541
Basic EPS (in usd per share)	$ 7.62	$ 12.56	$ 12.18
Diluted EPS (in usd per share)	$ 7.56	$ 12.49	$ 12.11

Collaborations - AstraZeneca PL

Collaborations - AstraZeneca PLC (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
AstraZeneca PLC | Cost of Sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Profit and loss share of expenses	$ 412	$ 310	$ 119

Collaborations - UCB (Details)

Collaborations - UCB (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
UCB | Cost of Sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Profit and loss share of expenses	$ 547	$ 396	$ 255

Collaborations - BeiGene (Detai

Collaborations - BeiGene (Details) - USD ($) $ in Millions		12 Months Ended
	Jan. 02, 2020	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues		$ 33,424	$ 28,190	$ 26,323
BeiGene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development arrangement, contract to provide cash and development services, maximum amount	$ 1,250
BeiGene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment, aggregate cost	$ 2,800
Research and Development Expense | BeiGene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost recoveries		122	109	199
BeiGene | BeiGene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues		$ 259	$ 125	$ 64

Collaborations - Kyowa Kirin (D

Collaborations - Kyowa Kirin (Details) - Kyowa Kirin Co. Ltd. - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payment	$ 400
Contingent future milestone payments		$ 850
Research and Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost recoveries		$ 166	$ 93	$ 23

Investments - Schedule of Avail

Investments - Schedule of Available-For-Sale Investments (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt securities
Amortized cost	$ 11,486	$ 10,404
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	11,486	10,404
U.S. Treasury bills
Debt securities
Amortized cost	997	0
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	997	0
Money market mutual funds
Debt securities
Amortized cost	10,354	10,266
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	10,354	10,266
Other short-term interest-bearing securities
Debt securities
Amortized cost	135	138
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	$ 135	$ 138

Investments - Schedule of Fair

Investments - Schedule of Fair Values by Classification (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Total available-for-sale investments	$ 11,486	$ 10,404
Available-for-sale investments
Debt Securities, Available-for-sale [Line Items]
Cash and cash equivalents	11,486	10,404
Total available-for-sale investments	$ 11,486	$ 10,404

Investments - Available-For-Sal

Investments - Available-For-Sale (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Cash	$ 487	$ 540
Interest income	$ 510	$ 1,200	$ 127

Investments - BeiGene (Details)

Investments - BeiGene (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 02, 2020
Net Investment Income [Line Items]
Unrealized gain on equity securities	$ (21)	$ 98	$ (165)
Equity securities	4,188	4,514
Company's share of profits (losses) of related party	10	(11)	(891)
Other Noncurrent Assets
Net Investment Income [Line Items]
Equity securities	$ 314	$ 494
BeiGene
Net Investment Income [Line Items]
Ownership percentage				20.50%
BeiGene | Maximum
Net Investment Income [Line Items]
Ownership percentage	5%	5%
BeiGene
Net Investment Income [Line Items]
Equity method investment, aggregate cost				$ 2,800
Unrealized gain on equity securities	$ 82	$ 1,200
Company's share of profits (losses) of related party			(394)
Amortization of the basis difference			190
Increase in carrying value of equity method investment			$ 11
BeiGene | BeiGene | Other Noncurrent Assets
Net Investment Income [Line Items]
Equity securities	$ 3,500	$ 3,400

Investments - Other Equity Secu

Investments - Other Equity Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity securities	$ 4,188	$ 4,514
Unrealized gain (loss) on equity method investment	(21)	98	$ (165)
Sale of unrealized gains (losses) on equity securities	0	0	0
Increase and decrease in equity securities without readily determinable fair value, amount	0	0
Adjustments to carrying value of securities without readily determinable fair value			$ 67
Other Noncurrent Assets
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity securities	314	494
Equity securities without readily determinable fair value	$ 319	$ 309

Investments - Neumora Therapeut

Investments - Neumora Therapeutics, Inc. (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Equity securities	$ 4,188	$ 4,514
Unrealized gain (loss) on equity method investment	$ (21)	$ 98	$ (165)
Neumora Therapeutics, Inc.
Schedule of Equity Method Investments [Line Items]
Ownership percentage	21.90%	23.20%
Equity securities	$ 375	$ 603
Unrealized gain (loss) on equity method investment	$ (228)	$ 238	$ 105
Neumora Therapeutics, Inc. | Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	5%
Neumora Therapeutics, Inc. | Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	10%

Investments - Limited Partnersh

Investments - Limited Partnership Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net Investment Income [Line Items]
Investment, Type [Extensible Enumeration]	Partnership Interest [Member]	Partnership Interest [Member]
Fair Value Measured at Net Asset Value Per Share
Net Investment Income [Line Items]
Alternative investments	$ 262	$ 251
Unfunded additional commitments	133
Net gains (losses) from limited partnership investments	$ 0	$ 0	$ (284)

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 818	$ 993
Work in process	4,120	5,747
Finished goods	2,060	2,778
Total inventories	$ 6,998	$ 9,518

Property, plant and equipment -

Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 16,931	$ 15,749
Less accumulated depreciation and amortization	(10,388)	(9,808)
Property, plant and equipment, net	6,543	5,941
Depreciation and amortization charges associated with property, plant and equipment	694	685	$ 661
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	346	339
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 4,803	4,507
Buildings and improvements | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years
Buildings and improvements | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	40 years
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 3,291	3,220
Manufacturing equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	8 years
Manufacturing equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,345	1,346
Laboratory equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	8 years
Laboratory equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Fixed equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Property, plant and equipment, gross	$ 2,592	2,526
Capitalized software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,442	1,320
Capitalized software | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Capitalized software | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Other
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,059	941
Other | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Other | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 2,053	$ 1,550

Property, plant and equipment_2

Property, plant and equipment - Schedule of Property, Plant and Equipment by Geographic Area (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 6,543	$ 5,941
U.S.
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	4,156	3,658
Puerto Rico
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	1,174	1,148
ROW
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 1,213	$ 1,135

Goodwill and other intangible_3

Goodwill and other intangible assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Beginning balance	$ 18,629	$ 15,529
Changes to goodwill resulting from acquisitions, net	25	3,089
Foreign currency translation adjustments	(17)	11
Ending balance	$ 18,637	$ 18,629

Goodwill and other intangible_4

Goodwill and other intangible assets - Schedule of Other Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Finite-lived intangible assets:
Gross carrying amounts	$ 55,062	$ 55,229
Accumulated amortization	(28,423)	(23,806)
Other intangible assets, net	26,639	31,423
Indefinite-lived intangible assets:
Identifiable intangible assets	56,122	56,447
Accumulated amortization	(28,423)	(23,806)
Identifiable intangible assets, net	27,699	32,641
In-process research and development
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	1,060	1,218
Developed-product-technology rights
Finite-lived intangible assets:
Gross carrying amounts	48,611	48,631
Accumulated amortization	(22,594)	(18,049)
Other intangible assets, net	26,017	30,582
Licensing rights
Finite-lived intangible assets:
Gross carrying amounts	3,875	3,865
Accumulated amortization	(3,392)	(3,265)
Other intangible assets, net	483	600
Marketing-related rights
Finite-lived intangible assets:
Gross carrying amounts	1,202	1,339
Accumulated amortization	(1,202)	(1,264)
Other intangible assets, net	0	75
R&D technology rights
Finite-lived intangible assets:
Gross carrying amounts	1,374	1,394
Accumulated amortization	(1,235)	(1,228)
Other intangible assets, net	$ 139	$ 166

Goodwill and other intangible_5

Goodwill and other intangible assets - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]		Other General Expense
Amortization charges associated with finite-lived intangible assets	$ 4,800	$ 3,200	$ 2,600
Total estimated amortization of finite-lived intangible assets for 2025	4,500
Total estimated amortization of finite-lived intangible assets for 2026	3,900
Total estimated amortization of finite-lived intangible assets for 2027	3,900
Total estimated amortization of finite-lived intangible assets for 2028	2,900
Total estimated amortization of finite-lived intangible assets for 2029	2,200
In-process research and development
Finite-Lived Intangible Assets [Line Items]
IPR&D impairment charge		783
Indefinite-lived intangible assets (excluding goodwill)	1,060	$ 1,218
Developed-product-technology rights
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	$ 5,200

Leases - Narrative (Details)

Leases - Narrative (Details)	Dec. 31, 2024
Leases [Abstract]
Renewal term (in years)	10 years

Leases - Schedule of Operating

Leases - Schedule of Operating Leases (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Assets:
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Other noncurrent assets	$ 557	$ 651
Liabilities:
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued Liabilities, Current	Accrued Liabilities, Current
Accrued liabilities	$ 107	$ 119
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Other noncurrent liabilities	$ 673	$ 691
Total lease liabilities	$ 780	$ 810

Leases - Schedule of Components

Leases - Schedule of Components of Lease Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating	$ 219	$ 208	$ 218
Sublease income	(17)	(28)	(32)
Total net lease costs	$ 202	$ 180	$ 186

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Lessee, Lease, Description [Line Items]
2025	$ 110
2026	129
2027	112
2028	91
2029	73
Thereafter	426
Total lease payments	941
Less imputed interest	(161)
Present value of lease liabilities	780	$ 810
Abandoned Leases
Lessee, Lease, Description [Line Items]
Future rental commitments for abandoned leases	51
Expected total future rental income to be received	$ 54

Leases - Schedule of Weighted A

Leases - Schedule of Weighted Average Remaining Lease Terms & Discount Rates (Details)	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted-average remaining lease term (in years)	9 years 3 months 18 days	9 years 8 months 12 days
Weighted-average discount rate	3.70%	3.60%

Leases - Schedule of Cash and N

Leases - Schedule of Cash and Noncash Information of Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating cash flows for operating leases	$ 156	$ 182	$ 171
Operating leases	$ 126	$ 245	$ 191

Other current assets and accr_3

Other current assets and accrued liabilities - Schedule of Other Current Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Prepaid expenses	$ 2,139	$ 1,647
Corporate partner receivables	521	502
Tax receivables	198	172
Other	419	281
Total other current assets	$ 3,277	$ 2,602

Other current assets and accr_4

Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Sales deductions	$ 8,405	$ 7,271
Income taxes payable	2,583	1,664
Employee compensation and benefits	1,329	1,381
Dividends payable	1,278	1,205
Accrued interest payable	867	936
Other	3,179	2,902
Total accrued liabilities	$ 17,641	$ 15,359

Financing arrangements - Schedu

Financing arrangements - Schedule of Borrowings (Details) $ in Millions	Dec. 31, 2024 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2024 GBP (£)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Unamortized bond discounts, premiums and issuance costs, net	$ (1,360)			$ (1,420)
Fair value adjustments	(343)			(314)
Other	24			17
Total carrying value of debt	60,099			64,613
Less current portion	(3,550)			(1,443)
Total long-term debt	56,549			63,170
Notes
Debt Instrument [Line Items]
Principal Amount	0				$ 24,000	$ 7,000
Total principal amount of debt	61,778			66,330
Total carrying value of debt	$ 58,300			60,600
3.625% notes due 2024 (3.625% 2024 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%	3.625%
Total principal amount of debt	$ 0			1,400
1.90% notes due 2025 (1.90% 2025 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	1.90%	1.90%	1.90%
Total principal amount of debt	$ 500			500
5.25% notes due 2025 (5.25% 2025 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%	5.25%	5.25%
Principal Amount					2,000
Total principal amount of debt	$ 2,000			2,000
Term loan due April 2025 | Secured Debt
Debt Instrument [Line Items]
Total principal amount of debt	$ 0			2,000
3.125% notes due 2025 (3.125% 2025 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%	3.125%	3.125%
Total principal amount of debt	$ 1,000			1,000
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2%	2%	2%
Principal Amount | €		€ 750,000,000
Total principal amount of debt	$ 777			828
5.507% notes due 2026 (5.507% 2026 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.507%	5.507%	5.507%
Principal Amount					1,500
Total principal amount of debt	$ 1,500			1,500
2.60% notes due 2026 (2.60% 2026 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%	2.60%	2.60%
Total principal amount of debt	$ 1,250			1,250
Term loan due October 2026 | Secured Debt
Debt Instrument [Line Items]
Total principal amount of debt	$ 1,800			2,000
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%	5.50%	5.50%
Principal Amount | £			£ 475,000,000
Total principal amount of debt	$ 595			605
2.20% notes due 2027 (2.20% 2027 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%	2.20%			2.20%
Total principal amount of debt	$ 1,724			1,724
3.20% notes due 2027 (3.20% 2027 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.20%	3.20%	3.20%
Total principal amount of debt	$ 1,000			1,000
5.15% notes due 2028 (5.15% 2028 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%	5.15%	5.15%
Principal Amount					3,750
Total principal amount of debt	$ 3,750			3,750
1.65% notes due in 2028 (1.65% 2028 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	1.65%	1.65%	1.65%			1.65%
Total principal amount of debt	$ 1,234			1,234
3.00% notes due 2029 (3.00% 2029 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3%	3%	3%			3%
Principal Amount						$ 750
Total principal amount of debt	$ 750			750
4.05% notes due 2029 (4.05% 2029 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.05%	4.05%	4.05%			4.05%
Principal Amount						$ 1,250
Total principal amount of debt	$ 1,250			1,250
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4%	4%	4%
Principal Amount | £			£ 700,000,000
Total principal amount of debt	$ 876			892
2.45% notes due 2030 (2.45% 2030 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%	2.45%	2.45%
Total principal amount of debt	$ 1,250			1,250
5.25% notes due 2030 (5.25% 2030 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%	5.25%	5.25%
Principal Amount					2,750
Total principal amount of debt	$ 2,750			2,750
2.30% notes due 2031 (2.30% 2031 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.30%	2.30%	2.30%
Total principal amount of debt	$ 1,250			$ 1,250
2.00% notes due 2032 (2.00% 2032 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2%	2%	2%	2%		2%
Total principal amount of debt	$ 1,001			$ 1,001
3.35% notes due 2032 (3.35% 2032 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.35%	3.35%	3.35%			3.35%
Principal Amount						$ 1,000
Total principal amount of debt	$ 1,000			1,000
4.20% notes due 2033 (4.20% 2033 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.20%	4.20%	4.20%			4.20%
Principal Amount						$ 750
Total principal amount of debt	$ 750			750
5.25% notes due 2033 (5.25% 2033 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%	5.25%	5.25%
Principal Amount					4,250
Total principal amount of debt	$ 4,250			4,250
6.375% notes due 2037 (6.375% 2037 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%	6.375%	6.375%
Total principal amount of debt	$ 478			478
6.90% notes due 2038 (6.90% 2038 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	6.90%	6.90%	6.90%
Total principal amount of debt	$ 254			254
6.40% notes due 2039 (6.40% 2039 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	6.40%	6.40%	6.40%
Total principal amount of debt	$ 333			$ 333
3.15% notes due 2040 (3.15% 2040 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.15%	3.15%	3.15%	3.15%
Total principal amount of debt	$ 1,668			$ 1,803
5.75% notes due 2040 (5.75% 2040 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%	5.75%	5.75%
Total principal amount of debt	$ 373			$ 373
2.80% notes due 2041 (2.80% 2041 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.80%	2.80%	2.80%	2.80%		2.80%
Total principal amount of debt	$ 776			$ 949
4.95% notes due 2041 (4.95% 2041 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.95%	4.95%	4.95%
Total principal amount of debt	$ 600			600
5.15% notes due 2041 (5.15% 2041 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%	5.15%	5.15%
Total principal amount of debt	$ 729			729
5.65% notes due 2042 (5.65% 2042 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%	5.65%	5.65%
Total principal amount of debt	$ 415			415
5.60% notes due 2043 (5.60% 2043 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.60%	5.60%	5.60%
Principal Amount					2,750
Total principal amount of debt	$ 2,750			2,750
5.375% notes due 2043 (5.375% 2043 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.375%	5.375%	5.375%
Total principal amount of debt	$ 185			185
4.40% notes due 2045 (4.40% 2045 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%	4.40%	4.40%
Total principal amount of debt	$ 2,250			2,250
4.563% notes due 2048 (4.563% 2048 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%	4.563%	4.563%
Total principal amount of debt	$ 1,415			$ 1,415
3.375% notes due 2050 (3.375% 2050 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.375%	3.375%	3.375%	3.375%
Total principal amount of debt	$ 1,764			$ 2,132
4.663% notes due 2051 (4.663% 2051 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%	4.663%	4.663%
Total principal amount of debt	$ 3,541			$ 3,541
3.00% notes due 2052 (3.00% 2052 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3%	3%	3%	3%		3%
Total principal amount of debt	$ 890			$ 999
4.20% notes due 2052 (4.20% 2052 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.20%	4.20%	4.20%	4.20%		4.20%
Principal Amount						$ 1,000
Total principal amount of debt	$ 895			$ 950
4.875% notes due 2053 (4.875% 2053 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.875%	4.875%	4.875%			4.875%
Principal Amount						$ 1,000
Total principal amount of debt	$ 1,000			1,000
5.65% notes due 2053 (5.65% 2053 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%	5.65%	5.65%
Principal Amount					4,250
Total principal amount of debt	$ 4,250			4,250
2.77% notes due 2053 (2.77% 2053 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.77%	2.77%	2.77%
Total principal amount of debt	$ 940			$ 940
4.40% notes due 2062 (4.40% 2062 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%	4.40%	4.40%	4.40%		4.40%
Principal Amount						$ 1,250
Total principal amount of debt	$ 1,165			$ 1,200
5.75% notes due 2063 (5.75% 2063 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%	5.75%	5.75%
Principal Amount					$ 2,750
Total principal amount of debt	$ 2,750			2,750
Other notes due 2097 | Notes
Debt Instrument [Line Items]
Total principal amount of debt	$ 100			$ 100

Financing arrangements - Miscel

Financing arrangements - Miscellaneous (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt securities payable | Minimum
Debt Instrument [Line Items]
Redemption period without payment of make whole amount	1 month
Debt securities payable | Maximum
Debt Instrument [Line Items]
Redemption period without payment of make whole amount	6 months
3.625% notes due 2024 (3.625% 2024 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
3.00% notes due 2029 (3.00% 2029 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3%		3%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.30% notes due 2031 (2.30% 2031 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.30%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
3.35% notes due 2032 (3.35% 2032 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.35%		3.35%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.20% notes due 2033 (4.20% 2033 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.20%		4.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
6.90% notes due 2038 (6.90% 2038 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	6.90%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
6.40% notes due 2039 (6.40% 2039 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	6.40%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
3.15% notes due 2040 (3.15% 2040 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.15%	3.15%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.563% notes due 2048 (4.563% 2048 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%
Effective interest rate on note	6.30%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.663% notes due 2051 (4.663% 2051 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%
Effective interest rate on note	5.60%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.77% notes due 2053 (2.77% 2053 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.77%
Effective interest rate on note	5.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.40% notes due 2045 (4.40% 2045 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.95% notes due 2041 (4.95% 2041 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.95%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
3.00% notes due 2052 (3.00% 2052 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3%	3%	3%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
3.375% notes due 2050 (3.375% 2050 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.375%	3.375%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.375% notes due 2043 (5.375% 2043 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.375%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.40% notes due 2062 (4.40% 2062 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%	4.40%	4.40%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.15% notes due 2041 (5.15% 2041 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.875% notes due 2053 (4.875% 2053 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.875%		4.875%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
3.125% notes due 2025 (3.125% 2025 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.75% notes due 2040 (5.75% 2040 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
6.375% notes due 2037 (6.375% 2037 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.60% notes due 2026 (2.60% 2026 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
1.65% notes due in 2028 (1.65% 2028 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	1.65%		1.65%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
3.20% notes due 2027 (3.20% 2027 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	3.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.65% notes due 2042 (5.65% 2042 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.20% notes due 2027 (2.20% 2027 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%		2.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.45% notes due 2030 (2.45% 2030 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.05% notes due 2029 (4.05% 2029 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.05%		4.05%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
4.20% notes due 2052 (4.20% 2052 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4.20%	4.20%	4.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.507% Notes Due 2026 | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.507%
5.507% Notes Due 2026 | Debt securities payable
Debt Instrument [Line Items]
Redemption period without payment of make whole amount	2 years
1.90% notes due 2025 (1.90% 2025 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	1.90%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.25% notes due 2025 (5.25% 2025 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.507% notes due 2026 (5.507% 2026 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.507%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.15% notes due 2028 (5.15% 2028 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.25% notes due 2030 (5.25% 2030 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.00% notes due 2032 (2.00% 2032 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2%	2%	2%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.25% notes due 2033 (5.25% 2033 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
2.80% notes due 2041 (2.80% 2041 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2.80%	2.80%	2.80%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.60% notes due 2043 (5.60% 2043 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.60%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.65% notes due 2053 (5.65% 2053 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%
5.75% notes due 2063 (5.75% 2063 Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101%

Financing arrangements - Sche_2

Financing arrangements - Schedule of Debt Issuances (Details) - Notes - USD ($) $ in Millions	Dec. 31, 2024	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal Amount	$ 0	$ 24,000	$ 7,000
5.25% 2025 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%
Principal Amount		2,000
5.507% 2026 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.507%
Principal Amount		1,500
5.15% 2028 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%
Principal Amount		3,750
5.25% 2030 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%
Principal Amount		2,750
5.25% 2033 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.25%
Principal Amount		4,250
5.60% 2043 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.60%
Principal Amount		2,750
5.65% 2053 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%
Principal Amount		4,250
5.75% 2063 Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%
Principal Amount		$ 2,750

Financing arrangements - Debt I

Financing arrangements - Debt Issuances and Acquisition-Related Financing (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Oct. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Notes
Debt Instrument [Line Items]
Principal Amount	$ 0			$ 24,000	$ 7,000
Notes | 3.00% notes due 2029 (3.00% 2029 Notes)
Debt Instrument [Line Items]
Principal Amount					$ 750
Interest rate, stated percentage	3%				3%
Notes | 4.05% notes due 2029 (4.05% 2029 Notes)
Debt Instrument [Line Items]
Principal Amount					$ 1,250
Interest rate, stated percentage	4.05%				4.05%
Notes | 3.35% notes due 2032 (3.35% 2032 Notes)
Debt Instrument [Line Items]
Principal Amount					$ 1,000
Interest rate, stated percentage	3.35%				3.35%
Notes | 4.20% notes due 2033 (4.20% 2033 Notes)
Debt Instrument [Line Items]
Principal Amount					$ 750
Interest rate, stated percentage	4.20%				4.20%
Notes | 4.20% notes due 2052 (4.20% 2052 Notes)
Debt Instrument [Line Items]
Principal Amount					$ 1,000
Interest rate, stated percentage	4.20%	4.20%			4.20%
Notes | 4.875% notes due 2053 (4.875% 2053 Notes)
Debt Instrument [Line Items]
Principal Amount					$ 1,000
Interest rate, stated percentage	4.875%				4.875%
Notes | 4.40% notes due 2062 (4.40% 2062 Notes)
Debt Instrument [Line Items]
Principal Amount					$ 1,250
Interest rate, stated percentage	4.40%	4.40%			4.40%
Variable Rate Component Three | Term Loan Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate	1.225%
Horizon Therapeutics
Debt Instrument [Line Items]
Term loan credit agreement, total amount					$ 4,000
Term loan credit agreement, total borrowed			$ 4,000
Repayments of term loan credit agreement	$ 2,200
Term loan, outstanding	$ 1,800

Financing arrangements - Debt E

Financing arrangements - Debt Extinguishment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Repayments of debt	$ 3,600,000,000	$ 1,454,000,000	$ 0
Extinguishment of debt, amount	659,000,000	647,000,000	297,000,000
Gain on extinguishment of debt	$ 215,000,000	$ 225,000,000	78,000,000
Notes
Debt Instrument [Line Items]
Repayments of debt			$ 0
Notes | 3.15% notes due 2040 (3.15% 2040 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.15%	3.15%
Notes | 2.80% notes due 2041 (2.80% 2041 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.80%	2.80%	2.80%
Notes | 3.375% notes due 2050 (3.375% 2050 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3.375%	3.375%
Notes | 3.00% notes due 2052 (3.00% 2052 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	3%	3%	3%
Notes | 4.20% notes due 2052 (4.20% 2052 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.20%	4.20%	4.20%
Notes | 4.40% notes due 2062 (4.40% 2062 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%	4.40%	4.40%
Notes | 2.00% notes due 2032 (2.00% 2032 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2%	2%	2%
Notes | 2.20% notes due 2027 (2.20% 2027 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%		2.20%
Notes | 1.65% notes due in 2028 (1.65% 2028 Notes)
Debt Instrument [Line Items]
Interest rate, stated percentage	1.65%		1.65%
Notes | Term loan due April 2025
Debt Instrument [Line Items]
Repayments of debt	$ 2,000,000,000
Notes | Term loan due October 2026
Debt Instrument [Line Items]
Repayments of debt	200,000,000
Notes | 3.625% notes due 2024 (3.625% 2024 Notes)
Debt Instrument [Line Items]
Repayments of debt	$ 1,400,000,000
Interest rate, stated percentage	3.625%
Notes | 2.25% Notes Due 2023
Debt Instrument [Line Items]
Interest rate, stated percentage		2.25%
Notes | 0.41% Notes Due 2023
Debt Instrument [Line Items]
Interest rate, stated percentage		0.41%
Notes | Various Long-Term Notes
Debt Instrument [Line Items]
Repayments of debt	$ 875,000,000	$ 881,000,000	$ 378,000,000

Financing arrangements - Debt R

Financing arrangements - Debt Repayments (Details)	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 CHF (SFr)	Mar. 31, 2023 USD ($)
Debt Instrument [Line Items]
Repayments of debt	$ 3,600,000,000	$ 1,454,000,000	$ 0
Notes
Debt Instrument [Line Items]
Repayments of debt			0
Principal amount	0		$ 7,000,000,000		$ 24,000,000,000
Term loan due April 2025 | Notes
Debt Instrument [Line Items]
Repayments of debt	2,000,000,000
Term loan due October 2026 | Notes
Debt Instrument [Line Items]
Repayments of debt	200,000,000
3.625% notes due 2024 (3.625% 2024 Notes) | Notes
Debt Instrument [Line Items]
Repayments of debt	$ 1,400,000,000
Interest rate, stated percentage	3.625%
2.25% Notes Due 2023 | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage		2.25%		2.25%
Principal amount		$ 750,000,000
0.41% Notes Due 2023 | Cross-currency swap contract (losses) gains | Cash flow hedge
Debt Instrument [Line Items]
Notional amounts		$ 704,000,000
0.41% Notes Due 2023 | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage		0.41%		0.41%
Principal amount | SFr				SFr 700,000,000

Financing arrangements - Cross-

Financing arrangements - Cross-Currency Swaps (Details)	Dec. 31, 2024
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | Notes payable
Debt Instrument [Line Items]
Interest rate, stated percentage	2%
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	2%
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | Notes
Debt Instrument [Line Items]
Interest rate, stated percentage	4%

Financing arrangements - Shelf

Financing arrangements - Shelf Registration Statement and Other Facilities (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) renewal_options	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Commercial paper, maximum borrowing capacity		$ 2,500,000,000
Commercial paper		0	$ 0
Annual commitment fees for syndicated, unsecured, revolving credit agreement	0.09%
Line of credit
Debt Instrument [Line Items]
Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement	$ 4,000,000,000
Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks	$ 1,250,000,000
Initial commitment term of each bank which is a party to the agreement	5 years
Number of additional term extension options | renewal_options	2
Additional period for extension of commitment term	1 year
Basis spread on variable rate	0.50%
Amount outstanding under syndicated, unsecured, revolving credit facility		$ 0	$ 0
Line of credit | Variable Rate Component One
Debt Instrument [Line Items]
Basis spread on variable rate	1.01%
Line of credit | Variable Rate Component Two
Debt Instrument [Line Items]
Basis spread on variable rate	1.10%

Financing arrangements - Sche_3

Financing arrangements - Schedule of Contractual Maturities of Long-term Debt (Details) $ in Millions	Dec. 31, 2024 USD ($)
Maturities of Long-term Debt [Abstract]
2025	$ 3,500
2026	5,922
2027	2,724
2028	4,984
2029	2,876
Thereafter	41,772
Total	$ 61,778

Financing arrangements - Intere

Financing arrangements - Interest Costs (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Interest paid, net of interest rate and cross currency swaps	$ 3.3	$ 2.4	$ 1.2

Stockholders' equity - Narrativ

Stockholders' equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended													12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Stock repurchases (in shares)														700,000	0	26,100,000
Stock repurchases														$ 200		$ 6,300
Amount available for stock repurchases under a board approved stock repurchase plan	$ 6,800													$ 6,800
Common stock, dividends declared per share (in usd per share)	$ 2.38	$ 2.25	$ 2.25	$ 2.25	$ 2.25	$ 2.13	$ 2.13	$ 2.13	$ 2.13	$ 1.94	$ 1.94	$ 1.94	$ 1.94	$ 9.13	$ 8.64	$ 7.95
Income taxes expense (benefit) for unrealized gains and losses for cash flow hedges														$ 105	$ 6	$ 19
Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges and related reclassifications														$ (25)	$ (50)	$ 0
Preferred stock shares authorized (in shares)	5,000,000													5,000,000
Preferred stock, par value (in usd per share)	$ 0.0001													$ 0.0001
Preferred stock, shares outstanding (in shares)	0				0									0	0
Preferred stock, shares issued (in shares)	0				0									0	0
Accelerated stock repurchase agreement
Class of Stock [Line Items]
Stock repurchases (in shares)																24,800,000

Stockholders' equity - Schedule

Stockholders' equity - Schedule of Components of AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 6,232	$ 3,661	$ 6,700
Foreign currency translation adjustments	(76)	50	496
Unrealized gains	506	28	84
Reclassification adjustments to earnings	(117)	(222)	2
Other	(10)	42	2
Income taxes	(80)	44	(19)
Ending balance	5,877	6,232	3,661
Foreign currency translation adjustments
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(298)	(348)	(844)
Foreign currency translation adjustments	(76)	50	496
Unrealized gains	0	0	0
Reclassification adjustments to earnings	0	0	0
Other	0	0	0
Income taxes	0	0	0
Ending balance	(374)	(298)	(348)
Cash flow hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(22)	128	61
Foreign currency translation adjustments	0	0	0
Unrealized gains	506	28	84
Reclassification adjustments to earnings	(117)	(222)	2
Other	0	0	0
Income taxes	(80)	44	(19)
Ending balance	287	(22)	128
Other
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	31	(11)	(13)
Foreign currency translation adjustments	0	0	0
Unrealized gains	0	0	0
Reclassification adjustments to earnings	0	0	0
Other	(10)	42	2
Income taxes	0	0	0
Ending balance	21	31	(11)
AOCI
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(289)	(231)	(796)
Ending balance	$ (66)	$ (289)	$ (231)

Stockholders' equity - Schedu_2

Stockholders' equity - Schedule of Reclassifications Out of AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Product sales	$ 33,424	$ 28,190	$ 26,323
Other income (expense), net	506	2,833	(814)
Income before income taxes	4,609	7,855	7,346
Provision for income taxes	(519)	(1,138)	(794)
Net income	4,090	6,717	6,552
Reclassification out of AOCI | Cash flow hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	117	222	(2)
Provision for income taxes	(25)	(50)	0
Net income	92	172	(2)
Cross-currency swap contract (losses) gains | Reclassification out of AOCI | Cash flow hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income (expense), net	(75)	42	(233)
Cross-currency swap contract (losses) gains | Cash flow hedge | Reclassification out of AOCI | Cash flow hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income (expense), net	(75)	42	(233)
Product sales
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Product sales	32,026	26,910	24,801
Product sales | Foreign currency contract gains | Reclassification out of AOCI | Cash flow hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Product sales	192	180	231
Product sales | Foreign currency contract gains | Cash flow hedge | Reclassification out of AOCI | Cash flow hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Product sales	$ 192	$ 180	$ 231

Fair value measurement - Fair V

Fair value measurement - Fair Value of Financial Assets and Liabilities on Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Assets:
Available-for-sale securities:	$ 11,486	$ 10,404
Equity securities	4,188	4,514
Derivatives:
Total assets	16,094	15,063
Derivatives:
Contingent consideration obligations	106	96	$ 270	$ 342
Total liabilities	1,128	1,188
Foreign currency contract gains
Derivatives:
Derivative assets	420	145
Derivatives:
Derivative liabilities	8	116
Cross-currency swap contract (losses) gains
Derivatives:
Derivative assets	0	0
Derivatives:
Derivative liabilities	483	405
Interest rate swap contracts
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	531	571
Quoted prices in active markets for identical assets (Level 1)
Assets:
Equity securities	4,188	4,514
Derivatives:
Total assets	14,542	14,780
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) | Foreign currency contract gains
Derivatives:
Derivative assets	0	0
Derivatives:
Derivative liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) | Cross-currency swap contract (losses) gains
Derivatives:
Derivative assets	0	0
Derivatives:
Derivative liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) | Interest rate swap contracts
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
Significant other observable inputs (Level 2)
Assets:
Equity securities	0	0
Derivatives:
Total assets	1,552	283
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	1,022	1,092
Significant other observable inputs (Level 2) | Foreign currency contract gains
Derivatives:
Derivative assets	420	145
Derivatives:
Derivative liabilities	8	116
Significant other observable inputs (Level 2) | Cross-currency swap contract (losses) gains
Derivatives:
Derivative assets	0	0
Derivatives:
Derivative liabilities	483	405
Significant other observable inputs (Level 2) | Interest rate swap contracts
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	531	571
Significant unobservable inputs (Level 3)
Assets:
Equity securities	0	0
Derivatives:
Total assets	0	0
Derivatives:
Contingent consideration obligations	106	96
Total liabilities	106	96
Significant unobservable inputs (Level 3) | Foreign currency contract gains
Derivatives:
Derivative assets	0	0
Derivatives:
Derivative liabilities	0	0
Significant unobservable inputs (Level 3) | Cross-currency swap contract (losses) gains
Derivatives:
Derivative assets	0	0
Derivatives:
Derivative liabilities	0	0
Significant unobservable inputs (Level 3) | Interest rate swap contracts
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
U.S. Treasury bills
Assets:
Available-for-sale securities:	997	0
U.S. Treasury bills | Quoted prices in active markets for identical assets (Level 1)
Assets:
Available-for-sale securities:	0	0
U.S. Treasury bills | Significant other observable inputs (Level 2)
Assets:
Available-for-sale securities:	997	0
U.S. Treasury bills | Significant unobservable inputs (Level 3)
Assets:
Available-for-sale securities:	0	0
Money market mutual funds
Assets:
Available-for-sale securities:	10,354	10,266
Money market mutual funds | Quoted prices in active markets for identical assets (Level 1)
Assets:
Available-for-sale securities:	10,354	10,266
Money market mutual funds | Significant other observable inputs (Level 2)
Assets:
Available-for-sale securities:	0	0
Money market mutual funds | Significant unobservable inputs (Level 3)
Assets:
Available-for-sale securities:	0	0
Other short-term interest-bearing securities
Assets:
Available-for-sale securities:	135	138
Other short-term interest-bearing securities | Quoted prices in active markets for identical assets (Level 1)
Assets:
Available-for-sale securities:	0	0
Other short-term interest-bearing securities | Significant other observable inputs (Level 2)
Assets:
Available-for-sale securities:	135	138
Other short-term interest-bearing securities | Significant unobservable inputs (Level 3)
Assets:
Available-for-sale securities:	$ 0	$ 0

Fair value measurement - Schedu

Fair value measurement - Schedule of Contingent Consideration Obligations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Combination, Contingent Consideration [Roll Forward]
Beginning balance	$ 96	$ 270	$ 342
Payments	(8)	(9)	(7)
Net changes in valuations	18	(165)	(65)
Ending balance	$ 106	$ 96	$ 270

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Remeasurement of contingent consideration liability	$ 18	$ (165)	$ (65)
Carrying value of long-term debt, including current portion	60,099	64,613
Fixed-rate notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate fair value of long-term debt, including current portion	54,900	59,200
Carrying value of long-term debt, including current portion	$ 58,300	$ 60,600

Derivative instruments - Narrat

Derivative instruments - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments Gain Loss [Line Items]
Length of time hedged in foreign currency contracts	3 years
3.625% notes due 2024 (3.625% 2024 Notes) | Notes
Derivative Instruments Gain Loss [Line Items]
Interest rate, stated percentage	3.625%
5.25% 2033 Notes | Notes
Derivative Instruments Gain Loss [Line Items]
Interest rate, stated percentage	5.25%
Forward Contracts [Member] | Designated as Hedging Instrument
Derivative Instruments Gain Loss [Line Items]
Notional amounts	$ 7,200	$ 6,600	$ 6,000
Forward Contracts [Member] | Derivatives not designated as hedging instruments
Derivative Instruments Gain Loss [Line Items]
Notional amounts	148	457	$ 517
Interest rate swap contracts | 3.625% notes due 2024 (3.625% 2024 Notes)
Derivative Instruments Gain Loss [Line Items]
Notional amounts	1,400
Interest rate swap contracts | 5.25% 2033 Notes
Derivative Instruments Gain Loss [Line Items]
Notional amounts	$ 1,400
Interest rates	1.80%
Interest rate swap contracts | Designated as Hedging Instrument
Derivative Instruments Gain Loss [Line Items]
Notional amounts	$ 6,700	$ 6,700
Foreign Currency and Cross Currency Swaps
Derivative Instruments Gain Loss [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified	$ 170

Derivative instruments - Schedu

Derivative instruments - Schedule of Cross-Currency Swaps (Details) € in Millions, £ in Millions, $ in Millions	Dec. 31, 2024 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2024 GBP (£)
2.00% 2026 euro Notes | Notes
Derivative [Line Items]
Interest rate, stated percentage	2%	2%	2%
5.50% 2026 pound sterling Notes | Notes
Derivative [Line Items]
Interest rate, stated percentage	5.50%	5.50%	5.50%
4.00% 2029 pound sterling Notes | Notes
Derivative [Line Items]
Interest rate, stated percentage	4%	4%	4%
Cash flow hedge | Cross-currency swap contracts | 2.00% 2026 euro Notes
Derivative [Line Items]
Notional amounts	$ 833	€ 750
Cash flow hedge | Cross-currency swap contracts | 5.50% 2026 pound sterling Notes
Derivative [Line Items]
Notional amounts	747		£ 475
Cash flow hedge | Cross-currency swap contracts | 4.00% 2029 pound sterling Notes
Derivative [Line Items]
Notional amounts	$ 1,111		£ 700
Cash flow hedge | Cross-currency swap contracts | Euro Member Countries, Euro | 2.00% 2026 euro Notes
Derivative [Line Items]
Interest rates	2%	2%	2%
Cash flow hedge | Cross-currency swap contracts | United Kingdom, Pounds | 5.50% 2026 pound sterling Notes
Derivative [Line Items]
Interest rates	5.50%	5.50%	5.50%
Cash flow hedge | Cross-currency swap contracts | United Kingdom, Pounds | 4.00% 2029 pound sterling Notes
Derivative [Line Items]
Interest rates	4%	4%	4%
Cash flow hedge | Cross-currency swap contracts | United States of America, Dollars | 2.00% 2026 euro Notes
Derivative [Line Items]
Interest rates	3.90%	3.90%	3.90%
Cash flow hedge | Cross-currency swap contracts | United States of America, Dollars | 5.50% 2026 pound sterling Notes
Derivative [Line Items]
Interest rates	6%	6%	6%
Cash flow hedge | Cross-currency swap contracts | United States of America, Dollars | 4.00% 2029 pound sterling Notes
Derivative [Line Items]
Interest rates	4.60%	4.60%	4.60%

Derivative instruments - Sche_2

Derivative instruments - Schedule of Effective Portion of Unrealized Gain (Loss) Recognized in AOCI (Details) - Cash flow hedge - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	$ 506	$ 28	$ 84
Foreign currency forward contracts
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	585	(14)	308
Cross-currency swap contracts
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	(79)	73	(219)
Forward interest rate contracts
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	$ 0	$ (31)	$ (5)

Derivative instruments - Sche_3

Derivative instruments - Schedule of Interest Rate Derivatives (Details) - Notes payable - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Derivative [Line Items]
Notional amounts	$ 6,650	$ 6,650
3.625% 2024 Notes
Derivative [Line Items]
Interest rate, stated percentage	3.625%
Notional amounts	$ 0	$ 1,400
Interest rates		3.40%
3.125% 2025 Notes
Derivative [Line Items]
Interest rate, stated percentage	3.125%
Notional amounts	$ 1,000	$ 1,000
Interest rates	2.10%	2.10%
2.60% 2026 Notes
Derivative [Line Items]
Interest rate, stated percentage	2.60%
Notional amounts	$ 1,250	$ 1,250
Interest rates	2.10%	2.10%
2.45% 2030 Notes
Derivative [Line Items]
Interest rate, stated percentage	2.45%
Notional amounts	$ 1,000	$ 1,000
Interest rates	1.30%	1.30%
2.30% 2031 Notes
Derivative [Line Items]
Interest rate, stated percentage	2.30%
Notional amounts	$ 500	$ 500
Interest rates	1.10%	1.10%
5.25% 2033 Notes
Derivative [Line Items]
Interest rate, stated percentage	5.25%
Notional amounts	$ 1,400	$ 0
Interest rates	1.80%
4.663% 2051 Notes
Derivative [Line Items]
Interest rate, stated percentage	4.663%
Notional amounts	$ 1,500	$ 1,500
Interest rates	4.30%	4.30%

Derivative instruments - Sche_4

Derivative instruments - Schedule of Hedged Liabilities and Cumulative Amount (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Derivative [Line Items]
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	$ (343)	$ (314)
Current portion of long-term debt
Derivative [Line Items]
Carrying amounts of hedged liabilities	1,045	1,441
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	45	41
Carrying value with discontinued hedging relationships	56	69
Hedging adjustments on discontinued hedging relationships	56	69
Long-term debt
Derivative [Line Items]
Carrying amounts of hedged liabilities	5,152	4,788
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	(388)	(355)
Carrying value with discontinued hedging relationships	232	288
Hedging adjustments on discontinued hedging relationships	$ 132	$ 188

Derivative instruments - Sche_5

Derivative instruments - Schedule of Income and Expense Line Items (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Total revenues	$ 33,424	$ 28,190	$ 26,323
Other income (expense), net	506	2,833	(814)
Interest expense, net	(3,155)	(2,875)	(1,406)
Cross-currency swap contract (losses) gains | Reclassification out of Accumulated Other Comprehensive Income | Cash flow hedges
Derivative [Line Items]
Other income (expense), net	(75)	42	(233)
Interest rate swap contracts
Derivative [Line Items]
Gains (losses) on fair value hedging relationships, Hedged Items	29	(118)	716
Derivatives designated as hedging instruments	40	205	(636)
Product sales
Derivative [Line Items]
Total revenues	32,026	26,910	24,801
Product sales | Foreign currency forward contracts | Reclassification out of Accumulated Other Comprehensive Income | Cash flow hedges
Derivative [Line Items]
Total revenues	$ 192	$ 180	$ 231

Derivative instruments - Sche_6

Derivative instruments - Schedule of Fair Value of Derivatives (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Derivatives Fair Value [Line Items]
Derivative assets	$ 420	$ 145
Derivative liabilities	1,022	1,092
Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Derivative assets	420	145
Derivative liabilities	1,022	1,092
Designated as Hedging Instrument | Foreign currency forward contracts | Other current assets/ Other noncurrent assets
Derivatives Fair Value [Line Items]
Derivative assets	420	145
Designated as Hedging Instrument | Foreign currency forward contracts | Accrued liabilities/ Other noncurrent liabilities
Derivatives Fair Value [Line Items]
Derivative liabilities	8	116
Designated as Hedging Instrument | Cross-currency swap contracts | Other current assets/ Other noncurrent assets
Derivatives Fair Value [Line Items]
Derivative assets	0	0
Designated as Hedging Instrument | Cross-currency swap contracts | Accrued liabilities/ Other noncurrent liabilities
Derivatives Fair Value [Line Items]
Derivative liabilities	483	405
Designated as Hedging Instrument | Interest rate swap contracts | Other current assets/ Other noncurrent assets
Derivatives Fair Value [Line Items]
Derivative assets	0	0
Designated as Hedging Instrument | Interest rate swap contracts | Accrued liabilities/ Other noncurrent liabilities
Derivatives Fair Value [Line Items]
Derivative liabilities	$ 531	$ 571

Contingencies and commitments (

Contingencies and commitments (Details) $ in Billions

1 Months Ended

3 Months Ended

Apr. 17, 2023

Jun. 08, 2021 lawsuit

Apr. 30, 2019 claim lawsuit plaintiff

Dec. 31, 2024 USD ($) installment

Nov. 13, 2024 patent

Oct. 04, 2024 patent

Aug. 12, 2024 patent

May 28, 2024 patent

May 02, 2024 case

Apr. 11, 2024 case

Jan. 10, 2024 patent

Dec. 01, 2023 claim

Mar. 11, 2022 state

Loss Contingencies [Line Items]

U.S. repatriation tax commitments, number of annual installments | installment

8

Final U.S. repatriation tax payment | $

$ 1.8

Amgen Inc. et al. v. Celltrion Inc., et al | Pending Litigation

Loss Contingencies [Line Items]

Potential number of patents infringed upon

29

Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al | Pending Litigation

Loss Contingencies [Line Items]

Potential number of patents infringed upon

34

Amgen Inc. et al. v. Fresenius Kabi USA, LLC et al | Pending Litigation

Loss Contingencies [Line Items]

Potential number of patents infringed upon

33

Amgen Inc. et al. v. Accord et al | Pending Litigation

Loss Contingencies [Line Items]

Potential number of patents infringed upon

34

Sensipar Antitrust Class Actions | Pending Litigation

Loss Contingencies [Line Items]

Loss contingency, number of plaintiffs | plaintiff

4

Number of lawsuits | claim

2

Loss contingency, number of lawsuits filed | lawsuit

4

Number of states in which plaintiffs reside | state

10

Class action complaint response period

30 days

PAVBLU Patent Litigation | Pending Litigation

Loss Contingencies [Line Items]

Potential number of patents infringed upon

32

Number of litigation cases | case

5

Martin Derivative Action | Pending Litigation

Loss Contingencies [Line Items]

Loss contingency, number of additional claims | claim

2

ChemoCentryx, Inc. Securities Matters

Loss Contingencies [Line Items]

Number of class action law suits | lawsuit

2

Number of securities cases | case

2

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Allowance for doubtful accounts [Roll Forward]
Balance at beginning of period	$ 28	$ 22	$ 26
Additions charged to costs and expenses	13	6	0
Other additions	0	0	0
Deductions	(3)	0	(4)
Balance at end of period	$ 38	$ 28	$ 22